N222 Exam #2

Diabetes Mellitus

Type 1 vs. Type 2 Diabetes

Type 1 vs. Type 2 Diabetes:

• Type 1 Diabetes: Autoimmune destruction of pancreatic beta cells resulting in an absolute lack of insulin. Requires lifelong basal-bolus insulin therapy and frequently affects younger individuals.

• Type 2 Diabetes: Characterized by insulin resistance and relative insulin deficiency. Managed through diet, exercise, oral antidiabetic agents, or insulin.

Key Differences

Type 1 Diabetes (T1DM):

• Autoimmune destruction of pancreatic beta cells

• Absolute lack of insulin production

• Long preclinical period before insulin deficiency and hyperglycemia develop

• Requires insulin therapy for survival

• Can test positive for autoantibodies

• C-peptide levels (marker of insulin production) are low or absent

• Risk of diabetic ketoacidosis (DKA) due to excessive fat and protein breakdown

Type 2 Diabetes (T2DM):

• Most common form: Accounts for at least 90% of all diabetes cases

• Affects more than 34.2 million people in the United States

• Progressive disorder: Begins with insulin resistance, progresses to decreased insulin secretion

• Insulin resistance in muscle, liver, and adipose tissue

• Reduced number AND sensitivity of insulin receptors

• Patients can have normal or even elevated insulin levels yet still have high blood glucose

• Impaired postprandial (after-meal) glucose metabolism

• Strong hereditary component plus environmental factors

• Often associated with metabolic syndrome (hyperlipidemia, hypertension, increased clotting)

---

Similarities

Both types share:

• Impaired production and/or use of insulin

• The same organ-damaging consequences and complications from impaired glucose regulation

• Need for careful glucose monitoring and management

---

Pathophysiology Summary

T1DM = No insulin → glucose accumulates in blood → osmotic diuresis (polyuria, thirst) → protein/fat breakdown → weight loss → ketoacidosis risk

T2DM = Insulin resistance + eventual insulin deficiency → cells don't respond to insulin despite adequate/high levels → hyperglycemia → cardiovascular complications

Insulin therapy

Insulin Therapy & Antidiabetic Medications:

• Basal Insulin: Long-acting or intermediate-acting regimens (Lantus, Levemir, NPH) providing baseline control.

• Bolus Insulin: Short- or rapid-acting insulins (Humalog, Novolog, Apidra, Regular) taken with meals.

• Sulfonylureas (e.g., Glyburide/DiaBeta): Stimulate insulin secretion from beta cells^[1]. Nursing considerations: Monitor for hypoglycemia; avoid co-administration with beta-blockers, as they can mask hypoglycemic warning signs

Who Needs Insulin

• Required for all patients with Type 1 Diabetes (T1DM)

• Used in 20-30% of patients with Type 2 Diabetes (T2DM)

• Safety concerns for older adults: reduced vision, mobility/coordination problems, and decreased memory increase dosage error risk

---

Types and Concentrations

Insulin analogs: Synthetic human insulins with altered structure to change absorption rate and duration

Action types available:

• Rapid-acting

• Short-acting

• Intermediate-acting

• Long-acting

• Ultra-long-acting

Concentrations:

• U-100 (100 units/mL) - standard

• U-200 (200 units/mL)

• U-300 (300 units/mL)

• U-500 (500 units/mL) - reserved for very large doses

---

Insulin Regimens

Regimens attempt to replicate normal pancreatic insulin release: constant basal insulin between meals + additional prandial (mealtime) insulin

Single daily injection:

• One injection of intermediate-, long-, or ultra-long-acting insulin

• May combine with oral agents or GLP-1 for bolus coverage

• Assess effectiveness by monitoring fasting blood glucose

Multiple-component therapy (twice daily):

• Combines short-acting (regular) and intermediate-acting (NPH) insulin

• 2/3 of daily dose before breakfast, 1/3 before evening meal

• Bedtime snack may be needed to prevent nocturnal hypoglycemia

Intensified regimens (MDI):

• Basal dose (intermediate-, long-, or ultra-long-acting) PLUS

• Mealtime bolus doses (short- or rapid-acting)

• "Correction" doses for blood glucose above target range

• Dosage determined by blood glucose patterns

Continuous subcutaneous insulin infusion (CSII/insulin pump):

• Basal insulin = ~50% of total daily dose

• Remainder divided into premeal rapid-acting doses

---

Key Factors Affecting Insulin

Absorption affected by:

• Injection site (abdomen fastest)

• Injection technique and depth

• Timing and dose

• Physical activity

• Heat, massage, exercise increase absorption

Critical safety points:

• Changing insulin type affects blood glucose control - only under provider supervision

• Doses adjusted based on blood glucose monitoring results

Glucose monitoring and A1C

• Glucose Monitoring & Glycated Hemoglobin (HbA1c):

• Fasting Plasma Glucose: Normal is <100 mg/dL, Pre-diabetes is 100–125 mg/dL, and Diabetes diagnosis is >126 mg/dL.

• HbA1c Values: Normal range is 4–6%. The ADA target for good diabetic control is <7%. Values >8% indicate poor glycemic control requiring treatment modification.

A1C Testing

What A1C measures:

• Percentage of hemoglobin A that is irreversibly glycosylated

• Reflects glycemic control over the preceding 2-3 months (average lifespan of red blood cells)

• Not affected by recent blood glucose fluctuations

Target goals:

• Less than 7% for nonpregnant adults with diabetes (without significant hypoglycemia)

• Higher goals for patients with multiple comorbidities or living in institutions

Diagnostic criteria:

• Less than 5.7% = Normal

• 5.7-6.4% = Prediabetes

• Above 6.5% = Type 2 diabetes

Testing frequency:

• At least twice yearly for patients meeting treatment goals with stable control

• Quarterly for patients whose therapy changed or not at target range

Estimated Average Glucose (eAG):

• Mathematical conversion of A1C into average blood glucose (mg/dL)

• Helps patients understand long-term control in familiar units seen on their glucose meters

---

Blood Glucose Monitoring (BGM)

Purpose:

• Assesses effectiveness of management plan

• Assists with self-care decisions

• Prevents hypoglycemia and hyperglycemia

• Guides adjustments to drugs, diet, and activity

When to monitor frequently:

• During illness

• When experiencing hypoglycemia symptoms

• Before and after exercise

• When therapy changes

Technique:

• Prick selected site (finger, arm, thigh, hand)

• Very small blood sample needed

• Test strip reads glucose value (mg/dL or mmol/L)

• Results evaluated along with A1C and lab values

Accuracy factors:

• Falsely elevated: Anemia (low hematocrit)

• Falsely depressed: Polycythemia (high hematocrit)

• May be unreliable in hypoglycemic or severely hyperglycemic ranges

Common user errors:

• Insufficient blood drop

• Poor strip storage or expired strips

• Wrong code number on meter

• Expired meter

Infection control:

• Handwash before monitoring

• Never reuse lancets

• Don't share equipment

• Clean meter regularly

• Wear gloves when helping others

---

Continuous Glucose Monitoring (CGM)

• Measures interstitial fluid glucose every 1-5 minutes 24

• Sensors last 6-14 days

• Provides real-time data and alerts for dangerous levels

• Lag time of up to 30 minutes when glucose changing rapidly

• Always confirm extreme values or hypoglycemia symptoms with capillary glucose before treatment

Signs/Symptoms of Hyperglycemia

Hyperglycemia vs. Hypoglycemia:

• Hypoglycemia: Caused by excess insulin or insufficient carbohydrate intake.

• Hyperglycemia: Caused by insulin deficiency, missed doses, stress, or infection.

Classic Signs and Symptoms

Hyperglycemia leads to osmotic diuresis with dehydration and electrolyte loss. The hallmark symptoms include:

The "Three Ps":

• Polyuria – increased urinary output

• Polydipsia – excessive thirst

• Polyphagia – increased appetite

Additional common symptoms:

• Fruity odor to breath (from ketones)

• Weakness

• Unintentional weight loss

• Muscle wasting

• Vomiting

• Abdominal pain

---

Severe Hyperglycemia Warning Signs

Altered mental status:

• Ranges from total alertness to profound coma

• Confusion may be present

Respiratory changes:

• Kussmaul respirations – deep, rapid breathing pattern

• Occurs as the body attempts to correct metabolic acidosis by exhaling carbon dioxide

Progressive complications:

• Can quickly lead to shock and coma if untreated

• As ketones rise, blood pH decreases causing acidosis

---

Laboratory Findings

• Elevated serum glucose levels

• Jaundice (yellowing of skin)

• Dark urine

• Intermittent elevations detected by both fasting and nonfasting blood glucose monitoring

---

Critical Context

Severe hyperglycemia can lead to life-threatening complications:

Diabetic Ketoacidosis (DKA):

• Characterized by extreme hyperglycemia, ketones in serum, acidosis, dehydration, and electrolyte imbalances

• Without treatment, leads to coma and death

• Triggered by physical or emotional stress

Hyperosmolar Hyperglycemic Syndrome (HHS):

• Blood glucose may exceed 600 mg/dL

• Blood osmolarity may exceed 320 mOsm/L

• Ketone levels are absent or low (unlike DKA)

Signs/Symptoms of Hypoglycemia

Hyperglycemia vs. Hypoglycemia:

• Hypoglycemia: Caused by excess insulin or insufficient carbohydrate intake.

• Hyperglycemia: Caused by insulin deficiency, missed doses, stress, or infection.

Early Warning Signs (Peripheral Autonomic)

Hypoglycemia occurs when blood glucose falls below 70 mg/dL (3.9 mmol/L). Early symptoms result from autonomic nervous system activation and serve as a warning system before brain glucose deprivation occurs:

• Sweating

• Irritability

• Tremors

• Anxiety

• Tachycardia (rapid heart rate)

• Hunger

---

Late/Severe Signs (Neuroglycopenic)

When brain glucose gradually declines to critically low levels, central nervous system (CNS) manifestations develop:

• Confusion

• Paralysis

• Seizures

• Coma

• Hypothermia

---

Progression Pattern

Neurologic symptoms occur when blood glucose declines rapidly

Neuroglycopenic symptoms occur when brain glucose gradually declines to low levels

---

Critical Context

Without adequate restoration of normal blood and CNS glucose levels, progression leads to coma and death

The brain requires a constant amount of glucose to function, making hypoglycemia a medical emergency that must be treated promptly.

---

Patient Education Points

Teach patients and families:

• Recognize all hypoglycemia symptoms early

• Delaying a meal for more than 30 minutes raises hypoglycemia risk with certain insulin regimens

• Keep a carbohydrate source nearby at all times

• How to inject glucagon for severe episodes

Important distinction: Hypoglycemia symptoms may be confused with severe hyperglycemia by family members; review the differences between these two emergencies

---

Risk Factors

Hypoglycemia is a common adverse effect when diabetes drugs have greater-than-expected pharmacologic effects. Contributing factors include:

• Skipped or delayed meals

• Increased physical activity

• Incorrect insulin dosing

• Medication interactions

Hyperglycemia vs. Hypoglycemia presentation and signs/symptoms difference

Hyperglycemia vs. Hypoglycemia:

• Hypoglycemia: Caused by excess insulin or insufficient carbohydrate intake.

• Hyperglycemia: Caused by insulin deficiency, missed doses, stress, or infection.

Main Differences at a Glance

Feature	Hyperglycemia	Hypoglycemia
Blood glucose level	Elevated (often >250 mg/dL)	Low (<70 mg/dL)
Onset	Gradual (hours to days)	Rapid (minutes)
Skin	Dry, flushed	Sweaty, cool
Breathing	Deep, rapid (Kussmaul)	Normal or shallow
Breath odor	Fruity (acetone)	Normal
Mental status	Confusion → coma	Irritability, confusion → seizures, coma

DKA vs HHS (manifestations, ABGs, management)

• Diabetic Ketoacidosis (DKA):

• Population & Onset: Primarily Type 1 Diabetes; rapid onset (<24 hours).

• Precipitating Factors: Infection (most common), missed insulin, MI, CVA, or physical/emotional stress. Leading cause of death in children/young adults with T1DM.

• Manifestations: Kussmaul respirations, fruity breath odor, diffuse abdominal pain, poor skin turgor, tachycardia, and hypotension.

• Lab Profile: Blood glucose >250 mg/dL, arterial pH <7.3 (metabolic acidosis), and positive serum/urine ketones.

• Hyperglycemic-Hyperosmolar State (HHS):

• Population & Onset: Primarily older adults with Type 2 Diabetes; gradual onset over days to weeks.

• Manifestations: Severe dehydration, polyuria, polydipsia, profound lethargy, altered mental status, and focal neurological deficits/seizures.

• Lab Profile: Blood glucose >600 mg/dL, serum osmolality >320 mOsm/L, arterial pH >7.3, and negative/low ketones. Higher mortality rate than DKA.

• Emergency Management for DKA & HHS: Remember FIE — Fluids (rapid rehydration), Insulin administration, and Electrolyte replacement (monitoring potassium closely)

Key Differences: DKA vs HHS

Feature	DKA	HHS
Typical diabetes type	Both types (historically T1DM)	Both types (historically T2DM)
Onset	Rapid	Gradual
Blood glucose	Elevated	More profound hyperglycemia (often >600 mg/dL)
Ketones	Present in serum	Absent or low
pH/Acidosis	Metabolic acidosis (pH <7.30)	No metabolic acidosis
Osmolarity	Elevated	Severe hyperosmolarity (>320 mOsm/L)

---

Manifestations

DKA:

• Polyuria, polydipsia, polyphagia

• Fruity breath odor

• Vomiting and abdominal pain

• Weakness

• Kussmaul respirations (deep, rapid breathing)

• Confusion or altered mental status (ranges from alert to coma)

HHS:

• Severe dehydration

• Loss of electrolytes (especially potassium)

• Neurologic changes including cerebral edema

• Coma

• No fruity breath or Kussmaul respirations (no ketoacidosis)

---

ABG Findings

DKA:

• Metabolic acidosis as ketones rise and blood pH decreases

• Respiratory alkalosis develops as Kussmaul respirations attempt to correct acidosis by exhaling carbon dioxide

• Venous pH <7.30 in unresolved DKA

HHS:

• No metabolic acidosis (lesser insulin deficiency prevents lipolysis and ketone production)

---

Management

DKA:

• Regular insulin by continuous IV infusion (unless mild episode)

• Initial IV bolus, then continuous infusion to lower glucose 50-75 mg/dL/hr

• Potassium replacement after levels fall below 5.0 mEq/L to prevent hypokalemia

• Sodium bicarbonate only for severe acidosis (pH ≤7.0 or bicarbonate <5 mEq/L)

• Switch to subcutaneous insulin when patient tolerates oral fluids and ketosis stops

Resolution criteria: Glucose <200 mg/dL, bicarbonate >18 mEq/L, venous pH >7.30, anion gap <12 mEq/L

HHS:

• Aggressive hydration

• Insulin therapy

• Electrolyte replacement (especially potassium)

Both conditions:

• Most commonly precipitated by physical or emotional stress

• Now recognized to occur with either type of diabetes

Metabolic syndrome

Metabolic syndrome is a cluster of metabolic risk factors associated with central adiposity, obesity, hypertension, and abnormal lipid levels that significantly increases the risk for developing Type 2 Diabetes and cardiovascular disease.

It is formally diagnosed when a patient presents with a combination of the following criteria:

• Central Obesity: Waist circumference &gt; 40 inches in men and &gt; 35 inches in women.

• Dyslipidemia:

  • Plasma Triglycerides: ≥ 150 mg/dL.

  • HDL Cholesterol: < 40 mg/dL in men and < 50 mg/dL in women.

• Elevated Blood Pressure: Blood pressure ≥ 130/85 mmHg.

• Elevated Fasting Blood Glucose: Fasting blood sugar &gt; 100 mg/dL

Definition

Metabolic syndrome is a constellation of metabolic factors that significantly increase the risk for developing type 2 diabetes (T2DM) and cardiovascular disease.

---

Key Features

The syndrome includes:

• Central obesity (abdominal/visceral fat)

• Dyslipidemia (abnormal lipid levels)

  • Hypertriglyceridemia (elevated triglycerides)

  • Low HDL cholesterol

• Prehypertension or hypertension

• Elevated fasting plasma glucose (FPG)

---

Clinical Significance

Cardiovascular risk:

• Any of these health problems increase the rate of atherosclerosis

• Elevated risk for stroke, cardiovascular disease (CVD), and early death

Diabetes risk:

• The syndrome precedes the onset of T2DM2

• Insulin resistance often develops first, accompanied by cardiovascular risk factors

Associated complications:

• More than one-half of individuals with diabetes have hypertension

• Nearly one in five with primary hypertension have diabetes

• Increased clot formation risk

---

Pathophysiology

Insulin resistance:

• Reduced cell receptor response to insulin

• Often develops in genetically susceptible adults before T2DM onset2

Molecular mechanisms:

• Increased activation of the renin-angiotensin-aldosterone system (RAAS) and sympathetic nervous system (SNS)

• Mitochondrial dysfunction

• Excessive oxidative stress

• Abnormal renal function

• Systemic inflammation

Interconnected effects:

• The interactions among obesity, hypertension, insulin resistance, and lipid disorders result in high cardiovascular disease risk

---

Management Approach

Lipid screening:

• Recommended at first diabetes diagnosis

• Every 5 years if under age 40

• Every 1-2 years thereafter

Treatment goals:

• Lifestyle modifications as cornerstone: diet matching activity levels, complex carbohydrates, low-fat foods, adequate protein and fiber

• Obesity management improves glucose tolerance

• Cardiovascular risk reduction including lipid management

• Bariatric surgery for selected individuals with morbid obesity

Microvascular complications

1. Diabetic Nephropathy (Kidney Damage)

• Pathology: High blood glucose levels cause microvascular damage to the filtering units (glomeruli) inside the kidneys.

• Clinical Impact: Leads to progressive loss of kidney function, structural changes in the renal tissue, and eventually kidney failure. Over 200,000 individuals with diabetes require long-term dialysis or kidney transplantation due to end-stage renal disease.

---

2. Diabetic Retinopathy (Eye & Vision Complications)

• Pathology: Damage to the delicate capillaries supplying the retina, manifesting as venous beading and retinal hemorrhage.

• Prevalence: Affects approximately 28.5% of individuals with diabetes over age 40, posing a major risk for progressive vision impairment and blindness.

---

3. Diabetic Neuropathy (Nerve Deterioration)

• Pathology: Progressive deterioration of peripheral and autonomic nerves resulting from microvascular compromise, affecting 60% to 70% of diabetic patients.

• Sensory Manifestations: Causes paresthesias, foot deformities, and loss of protective sensation. Unnoticed foot injuries due to sensory loss are the most common complication leading to hospitalizations and amputations.

• Autonomic Manifestations: Involves systemic nerve impairment, including gastroparesis (delayed gastric emptying), orthostatic hypotension, syncope, and earlier onset of male erectile dysfunction

Overview

Microvascular complications result from damage to capillary vessels, which impairs peripheral circulation and damages the eyes, kidneys, and nerves. These complications are distinct from macrovascular complications (large vessel damage from atherosclerotic plaque).

---

Three Major Microvascular Complications

Diabetic Retinopathy (DR)

Prevalence and risk:

• Blindness is 25 times more common in patients with diabetes

• Strongly related to duration of diabetes

• After 20 years, nearly all patients have some degree of retinopathy

• Few symptoms until vision loss occurs

Types:

Nonproliferative DR:

• Structural problems in retinal vessels with poor circulation, edema, fatty deposits, and hemorrhages

• Fluid and blood leak causing retinal edema and hard exudates

• Develops slowly; rarely causes blindness

Proliferative DR:

• Growth of new, fragile blood vessels (neovascularization)

• Triggered by retinal hypoxia

• Vessels bleed easily, leading to vision loss

---

Diabetic Nephropathy

Significance:

• Diabetes is the leading cause of end-stage kidney disease (ESKD) in the United States

Pathophysiology:

• Chronic hyperglycemia causes hypertension in kidney blood vessels and excess tissue perfusion

• Vessels become leakier, allowing albumin and protein filtration

• Narrowed vessels decrease kidney oxygenation → cell death

• Progressive albumin excretion and declining GFR

Risk factors: Chronic hyperglycemia, hypertension, genetic predisposition

Prevention: Onset may be delayed or prevented by maintaining optimal blood glucose regulation

---

Diabetic Neuropathy

Peripheral Neuropathy (DPN):

• Progressive nerve deterioration resulting in sensory perception loss

• Affects both sides of the body, progresses, and is permanent

• Damage to sensory fibers: pain → loss of sensation

• Damage to motor fibers: muscle weakness

• Late complications: foot ulcers and deformities

Autonomic Neuropathy :

• Affects every organ system

• Cardiovascular: orthostatic hypotension, syncope, painless MI

• GI: delayed gastric emptying (gastroparesis), constipation, diarrhea

• Urinary: incomplete bladder emptying, retention, infection

Macrovascular complications

1. Cardiovascular Disease (CVD)

• Pathology & Impact: Coronary artery damage and atherosclerosis significantly increase the risk for Myocardial Infarction (MI).

• Clinical Significance: MI is the leading cause of death among diabetic patients.

---

2. Cerebrovascular Disease

• Pathology & Impact: Chronic vascular changes elevate the risk for a Cerebrovascular Accident (CVA / Stroke).

• Compounding Risk Factors: CVA risk increases when accompanied by hypertension, hyperlipidemia, nephropathy, peripheral vascular disease (PVD), smoking, or alcohol consumption.

• Glycemic Effect: Elevated blood glucose levels during an active CVA contribute to greater brain injury and higher patient mortality.

---

3. Peripheral Vascular Disease (PVD)

• Pathology & Impact: Arterial wall changes impair blood flow to the large vessels supplying the lower extremities.

• Clinical Impact: Contributes to impaired peripheral tissue perfusion, slow wound healing, and higher amputation risks when combined with diabetic neuropathy.

---

Preventive Targets & Medical Management

To slow macrovascular disease progression, current clinical guidelines emphasize:

• Blood Pressure Control: Maintain BP < 130/80 mmHg.

• Lipid Management: Maintain LDL < 100 mg/dL (or < 70 mg/dL in patients with known heart disease) and triglycerides < 150 mg/dL.

• Antiplatelet Therapy: Aspirin therapy is recommended for Type 1 and Type 2 diabetic patients at increased cardiovascular risk (including those over age 40)

Overview

Macrovascular complications result from large vessel damage caused by atherosclerotic plaque deposition, compromising both central and peripheral circulation 1. These complications are distinct from microvascular disease (capillary damage affecting eyes and kidneys).

---

Primary Macrovascular Complications

Cardiovascular Disease (CVD)

Risk profile:

• Primary cause of death in individuals with diabetes, with higher risk for females

• Patients with diabetes, prediabetes, or metabolic syndrome are at increased risk for CVD

• Nearly three-fourths of individuals with type 2 diabetes have hypertension

Contributing factors:

• Traditional CVD risk factors: obesity, hyperlipidemia, hypertension

• Cigarette smoking and family history

• Kidney disease (albuminuria) and retinopathy associated with increased coronary disease risk

Pathophysiology:

• Chronic vascular inflammation from hyperglycemia and insulin resistance

• Endothelial damage, vessel wall thickening, perivascular adipose tissue deposition

• Increased thrombosis and glycation of vascular proteins

• Decreased production of nitric oxide and other vasodilators

• Deleterious lipid changes: high LDL, low HDL

Coronary Artery Disease (CAD)

Mechanism :

• Vessel injury related to insulin resistance and hyperglycemia leading to accelerated atherosclerosis

Heart Failure

Incidence:

• Higher in individuals with diabetes, even without myocardial infarction5

• May relate to diabetic cardiomyopathy with increased ventricular collagen and hypertrophy

---

Management Goals

Target values:

• Blood pressure: <140/90 mm Hg (target 120/80 in younger adults if achievable)

• LDL cholesterol: <100 mg/dL without CVD; <70 mg/dL with CVD

Interventions:

• Smoking cessation, stress management, balanced diet

• Physical activity and weight loss (if indicated)

• Omega-3 fatty acids, fiber, plant sterols

• Prescribed lipid-lowering therapy and aspirin

• SGLT2 inhibitors may reduce atherosclerotic CVD risk

Liver Disorders

Hepatitis A

Hepatitis A (HAV)

• Transmission Route: Transmitted via the fecal-oral route through oral ingestion of fecal contaminants. Common sources include contaminated water, shellfish harvested from contaminated waters, food prepared by infected handlers, and oral-anal sexual activity.

• Incubation Period: 15 to 50 days.

• Clinical Presentation: Symptoms resemble a typical viral syndrome or gastrointestinal illness and frequently go unrecognized.

• Severity: Usually not life-threatening, though the disease course can be more severe in individuals over 40 years old.

General Nursing Management & Public Health

• Mandatory Reporting: All diagnosed cases of hepatitis must be reported to the local health department, which subsequently notifies the CDC.

• General Clinical Manifestations: Patients across viral hepatitis types may present with lethargy, malaise, fever, muscle pain (myalgia), joint pain (arthralgia), diarrhea or constipation, abdominal pain, and skin itching (pruritus).

• Core Nursing Interventions: Focus on promoting physical and psychological rest, providing tailored diet therapy, and administering medications sparingly to avoid extra strain on liver metabolism

Causative Agent

Hepatitis A virus (HAV) is an RNA virus that is hardy and survives on human hands, resistant to detergents and acids, but destroyed by chlorine (bleach) and extremely high temperatures.

---

Transmission

Primary route: Fecal-oral

• Person-to-person contact (e.g., oral-anal sexual activity)

• Contaminated food or water

• Common sources: shellfish from contaminated water and food handled by infected individuals

Incubation period: 15-50 days (peak 25-30 days)

---

Clinical Presentation

Typical course:

• Often mild and flulike, frequently goes unrecognized

• Similar to GI illness with usually uneventful recovery

• Some adults have it without knowing

Severe cases:

• More severe in adults >40 years and those with preexisting liver disease (e.g., hepatitis C)

• Can cause extrahepatic signs/symptoms

• May require liver transplant with widespread damage

• Death possible when immunity is decreased

---

Diagnosis

Laboratory findings:

• Elevated liver enzymes (ALT/AST may reach thousands in acute cases)

• Elevated serum total bilirubin (consistent with jaundice)

• HAV antibodies (HAV-Ab/IgM) confirm presence

• IgM antibodies indicate ongoing inflammation (persist 3-6 weeks)

• IgG antibodies indicate previous infection and permanent immunity

---

Prevention

Vaccination:

• Safe and effective for infants, children, adolescents, and some adults

• Combination HAV/HBV vaccine available for adults

• Has helped decrease incidence

Hygiene measures:

• Proper handwashing

• Avoiding contaminated food/water

• Sanitation improvements (incidence particularly high where sanitation is poor)

---

Nutritional Management

Dietary approach:

• High carbohydrate, high calorie diet

• Moderate fat and protein after nausea/anorexia subside

• Small, frequent meals preferred

• Focus on appealing food preferences

• High-calorie snacks and supplemental vitamins often needed

Hepatitis B

Hepatitis B (HBV)

• Transmission Route: Spread through blood and body fluids via unprotected sexual intercourse with an infected partner, sharing needles, accidental needle stick injuries, blood transfusions, hemodialysis, and maternal-fetal transmission.

• Incubation Period: 25 to 180 days post-exposure.

• Clinical Presentation: Characterized by anorexia, nausea, vomiting, fever, fatigue, right upper quadrant (RUQ) abdominal pain, dark urine, light/clay-colored stool, joint pain (arthralgia), and jaundice.

• Carrier Status: Patients can become carriers and spread the virus to others even if they are completely asymptomatic

General Nursing Management & Public Health

• Mandatory Reporting: All diagnosed cases of hepatitis must be reported to the local health department, which subsequently notifies the CDC.

• General Clinical Manifestations: Patients across viral hepatitis types may present with lethargy, malaise, fever, muscle pain (myalgia), joint pain (arthralgia), diarrhea or constipation, abdominal pain, and skin itching (pruritus).

• Core Nursing Interventions: Focus on promoting physical and psychological rest, providing tailored diet therapy, and administering medications sparingly to avoid extra strain on liver metabolism

Causative Agent & Structure

Hepatitis B virus (HBV) is a double-shelled particle containing DNA composed of 1:

• Core antigen (HBcAg)

• Surface antigen (HBsAg)

• e antigen (HBeAg) found within the core that circulates in blood

---

Transmission

NOT transmitted like hepatitis A (not fecal-oral)

Common modes include:

• Blood and body fluid exposure

• Sexual contact

• Perinatal transmission (mother to infant)

• Sharing contaminated needles/equipment

High-risk groups: Individuals with compromised immunity from disease or drug therapy are more likely to develop hepatitis B

---

Clinical Course

Incubation: 25-180 days after exposure

Symptoms: Many individuals have no symptoms

Outcomes:

• Most adults recover, clear the virus, and develop immunity

• Small percentage become carriers without symptoms but can still infect others

• Chronic carriers are at high risk for cirrhosis and liver cancer

---

Diagnosis

Key serologic markers:

• HBsAg (surface antigen) and IgM anti-HBcAg (antibodies to core antigen) are most significant

• Presence of these markers establishes diagnosis

• Patient is infectious as long as HBsAg is present

• Persistence of HBsAg ≥6 months indicates carrier state or chronic hepatitis

• HBsAg normally declines and disappears after acute episode

• Antibodies to HBsAg indicate recovery and immunity

• Positive HBsAg after vaccination also indicates immunity

---

Prevention

Vaccination:

• Safe and effective for infants, children, adolescents, and adults

• Part of Healthy People 2030 objectives

• Combination HAV/HBV vaccine available for adults

Recommended for:

• Healthcare workers and others in contact with infected patients

• High-risk populations (specific groups detailed in clinical guidelines)

Post-exposure prophylaxis:

• Hepatitis B immunoglobulin (passive immunity) for those exposed to HBV or HBsAg-positive materials

• Prepared from plasma donors with high antibody titers

• Can be used during pregnancy when clearly needed

NAFLD and vulnerable populations

1. Key Etiologies & Risk Factors

NAFLD is closely linked to systemic metabolic dysfunction. The primary contributing factors identified in your sources include:

• Obesity & Central Adiposity: Excess visceral fat increases lipid deposition in liver tissue.

• Diabetes Mellitus & Insulin Resistance: Elevated blood glucose and impaired insulin signaling alter hepatic lipid metabolism.

• Elevated Lipid Profile (Dyslipidemia): High serum triglycerides and low HDL levels drive fat accumulation in liver cells.

• Alcohol Misuse: While non-alcoholic steatosis is defined by metabolic causes, alcohol abuse significantly worsens hepatic fat accumulation and accelerates progression toward cirrhosis.

---

2. Vulnerable & High-Risk Populations

Certain patient populations face a significantly elevated risk for metabolic dysfunction and NAFLD progression:

• Racial & Ethnic Minorities: CDC statistics and lecture slides highlight higher rates of metabolic risk factors and diabetes among Black/African American (20.7%), Hispanic/Latino (17.1%), and Asian (14.5%) populations compared to White non-Hispanic individuals (11.2%).

• Older Adults (Geriatric Population): Over 52% of adults aged 65 and older have prediabetes. Age-related metabolic changes and decreased hormone secretion heighten vulnerability to fatty liver and silent metabolic complications.

• Individuals with Metabolic Syndrome: Patients meeting the criteria for Metabolic Syndrome (central obesity, elevated triglycerides, low HDL, elevated blood pressure, and fasting blood glucose >100 mg/dL) are at the highest risk for progressive liver damage.

---

3. Clinical Presentation

• Asymptomatic Early Course: Many patients with fatty liver are completely asymptomatic during early stages, making routine screening of high-risk metabolic patients vital.

• Progression Risk: If left unmanaged, chronic hepatic inflammation and fat accumulation can progress to cirrhosis, leading to irreversible scarring, portal hypertension, and end-stage liver failure.

Nonalcoholic Fatty Liver Disease (NAFLD): Definition

NAFLD occurs when the liver stores excessive amounts of fat unrelated to alcohol consumption 1. It is primarily related to obesity, increased cholesterol and triglycerides, type 2 diabetes mellitus, and metabolic syndrome.

---

Vulnerable PopulationsLatino/Hispanic Communities

Highest risk group:

• Individuals of Latino descent carry the PNPLA3 gene (patatin-like phospholipase domain-containing 3) more frequently

• This gene significantly increases NAFLD risk

• Makes this population the most vulnerable to developing NAFLD

Individuals with Obesity

Strong association:

• NAFLD is closely tied to obesity, including obese children

• Obesity leads to ectopic fat deposition in the liver

• Associated with altered adipocyte function, insulin resistance, and increased inflammation

People with Metabolic Conditions

High-risk factors:

• Type 2 diabetes mellitus

• Metabolic syndrome

• Insulin resistance

• High triglyceride levels

Individuals at Normal Weight

Lean MAFLD:

• Some lean, normal-weight individuals can develop metabolic dysfunction-associated fatty liver disease (MAFLD) when triglycerides exceed metabolic capacity

---

Prevalence & Progression

Current statistics:

• Prevalence has increased dramatically over the past decade

• Estimated 100 million Americans have NAFLD

Disease progression:

• Nearly 20% of those with NAFLD develop NASH (nonalcoholic steatohepatitis)

• NASH involves increased liver inflammation, hepatocyte injury, and fibrosis

• Advanced disease leads to cirrhosis, liver cancer, liver failure, and premature death

---

Prevention

Lifestyle modifications:

• Preventing obesity and practicing a healthy lifestyle can decrease NAFLD risk

What do I need to know about Cirrhosis and Portal hypertension?

Cirrhosis is extensive, irreversible scarring of the liver caused by chronic hepatic inflammation and cell necrosis. As scar tissue and nodular tissue develop, normal liver architecture is destroyed, blocking hepatic blood flow and bile ducts.

---

1. Etiology & Types of Cirrhosis

• Laennec’s Cirrhosis: Caused specifically by chronic alcoholic abuse.

• Postnecrotic Cirrhosis: Results from viral hepatitis (such as Hepatitis B or C) or exposure to hepatotoxic drugs and toxins (e.g., Tylenol).

• Biliary Cirrhosis: Triggered by chronic biliary obstruction or gallbladder (GB) disease.

• Other Causes: Include metabolic/genetic disorders and chronic cardiovascular disease.

---

2. Portal Hypertension & Secondary Complications

Portal hypertension is a primary major complication of cirrhosis caused by structural scar tissue compressing portal vessels and obstructing portal venous blood flow through the liver. Blood backs up into systemic circuits, leading to severe downstream complications

Portal Hypertension

Definition & Pathophysiology:

• Persistent increase in portal vein pressure from 3 mm Hg to at least 10 mm Hg

• Major complication of cirrhosis caused by increased resistance or obstruction to blood flow through the portal vein

• Most common cause: Fibrosis and obstruction from liver cirrhosis

Mechanism:

• Blood meets resistance and seeks collateral (alternative) venous channels

• Blood backs up into the spleen causing splenomegaly

• Veins throughout the GI tract become dilated

• Intrahepatic causes: vascular remodeling, thrombosis, inflammation, or fibrosis of sinusoids

---

Major Complications of Portal Hypertension

Varices

Esophageal and gastric varices:

• Distended, fragile, thin-walled veins from increased pressure

• Most common in distal esophagus but can occur in stomach, intestines, rectum

• Abdominal wall varices called caput medusae

Bleeding risk:

• Life-threatening emergency with potential for severe blood loss and hypovolemic shock

• Presents as hematemesis (vomiting blood) or melena (black, tarry stools)

• May cause loss of consciousness before visible bleeding

• Can occur spontaneously or triggered by activities increasing abdominal pressure, chest trauma, or rough food

Management:

• All cirrhosis patients screened by endoscopy to detect varices early

• Preventive therapy: Nonselective beta-blockers (e.g., propranolol) to decrease heart rate and hepatic venous pressure

• Antibiotics: Given on admission for GI bleeding (20% have infection on admission)

• Acute bleeding: Vasoactive drugs (octreotide, vasopressin) combined with endoscopic therapies

Ascites

• Free fluid collection in peritoneal cavity from increased hydrostatic pressure

• Decreased serum colloid osmotic pressure from low albumin production

• Results in fluid shift from vascular system into abdomen ("third spacing")

• Patient may have hypovolemia and edema simultaneously

• Massive ascites triggers renin-angiotensin system → more sodium/water retention → worsening cycle

What do I need to know about Cirrhosis and Ascites?

1. Pathophysiology

• Cirrhosis: Extensive, irreversible scarring of the liver caused by chronic hepatic inflammation and tissue necrosis. As nodular tissue develops, it blocks bile ducts and hepatic blood flow, leading to portal hypertension.

• Ascites: Accumulation of fluid within the peritoneal cavity caused primarily by portal hypertension and decreased hepatic synthesis of serum albumin.

---

2. Abdominal Assessment Findings

• Physical Signs: Patients present with abdominal enlargement, a protruding umbilicus, caput medusae (dilated abdominal veins radiating across the abdomen), and hepatomegaly.

• Abdominal Girth: Measure abdominal girth daily using a tape measure positioned across the abdomen at the point of largest diameter to evaluate fluid accumulation.

---

3. Clinical Impact & Positioning

• Respiratory Distress: Fluid accumulation places upward pressure on the diaphragm and lungs, causing dyspnea and shortness of breath. Ascites also exerts pressure on abdominal organs, contributing to constipation and decreased renal perfusion.

• Positioning for Comfort: Elevate the head of the bed (HOB) at least 30 degrees (or higher based on patient comfort) to relieve respiratory pressure. Encourage the patient to sit in a chair.

• Daily Weights: Weigh the patient in a standing position, as placing the patient flat/supine aggravates dyspnea.

---

4. Medical & Nursing Interventions

• Nutrition Therapy: Implement a low-sodium diet, restrict fluid intake as prescribed, and administer vitamin supplements.

• Pharmacology: Administer prescribed diuretics and monitor/replace electrolytes as needed.

• Paracentesis: Insertion of a trocar catheter into the abdomen to drain ascitic fluid directly from the peritoneal cavity.

• Critical Nursing Priority: Continuously assess for signs of impending hypovolemic shock during and following a paracentesis due to rapid fluid and intravascular volume shifts

Pathophysiology of Ascites in Cirrhosis

Multiple contributing factors:

• Portal hypertension: Capillary hydrostatic pressure exceeds osmotic pressure, pushing water into peritoneal cavity

• Increased hepatic lymph production that "weeps" into peritoneal cavity

• Decreased albumin synthesis: Reduces capillary oncotic pressure, worsening fluid shift

• Splanchnic arterial vasodilation: Increased nitric oxide from diseased liver decreases effective blood volume

• Renal sodium/water retention: Activates renin-angiotensin-aldosterone system and ADH, expanding plasma volume and accelerating portal hypertension

• Bacterial translocation and endotoxin release: Causes peritonitis with inflammation that increases mesenteric capillary permeability

---

Clinical Assessment

Physical findings:

• Massive ascites: Distended abdomen with bulging flanks

• Protruding umbilicus

• Caput medusae: Dilated abdominal veins radiating from umbilicus

• Minimal ascites: More difficult to detect, especially in obese patients

Complications:

• Orthopnea and dyspnea from abdominal distention interfering with lung expansion

• Difficulty maintaining erect posture and balance problems

• Inguinal or umbilical hernias from increased intraabdominal pressure

Monitoring:

• Measure abdominal girth to evaluate progression

• Patient lies flat; measure at largest diameter (usually umbilicus) at end of exhalation

• Mark skin/flanks to ensure consistent placement

---

Management

Nutrition therapy:

• Low-sodium diet (1-2 g daily) as initial control measure

• Eliminate table salt completely

• Use alternative flavorings: lemon, vinegar, parsley, oregano, pepper

• Read sodium content labels on all food/beverages

Paracentesis:

• Performed when ascites affects respiratory effort

• Invasive procedure to remove abdominal fluid from peritoneal cavity

• Done at bedside, interventional radiology, or ambulatory setting using ultrasound guidance

• Short-term or tunneled drains may be placed

• Fluid sample sent for cell count and culture if spontaneous bacterial peritonitis (SBP) suspected

What do I need to know about Cirrhosis and Esophageal varices?

Esophageal varices are complex, dilated, and extremely fragile submucosal veins that develop in the lower esophagus and stomach as a direct consequence of portal hypertension caused by cirrhosis.

---

1. Pathophysiology & Cause

• Mechanism: Extensive scarring and nodular tissue in cirrhosis block hepatic blood flow and bile ducts, elevating pressure in the portal venous system (portal hypertension).

• Vessel Dilation: To bypass the obstructed hepatic circulation, blood backs up into collateral veins, causing lower esophageal and gastric blood vessels to swell and become thin-walled.

---

2. Hemorrhage & Clinical Assessment

• Bleeding Risk: Esophageal varices carry a high risk for spontaneous, massive hemorrhage, making active bleeding a life-threatening medical emergency.

• Monitoring & Assessment: Assess for signs of gastrointestinal bleeding, including hematemesis (vomiting blood), melena (dark, tarry stools), and blood in nasogastric (NG) drainage.

• NG Tube Precaution: Avoid blind NG tube insertion or trauma, as physical contact can directly irritate, puncture, or rupture fragile varices.

---

3. Medical & Nursing Interventions

A. Prophylactic & Nonsurgical Management

• Beta-Blocker Therapy: Nonselective beta-blockers (such as propranolol) are prescribed to decrease portal venous pressure and reduce the risk of initial or recurrent bleeding.

B. Acute Hemorrhage Management

• Source Identification: Identify the bleeding site rapidly and initiate measures to halt hemorrhage.

• Fluid & Blood Resuscitation: Administer blood transfusions and IV fluids to restore intravascular volume and treat blood loss.

• Vasoactive Drug Therapy: Administer vasoactive medications to constrict visceral blood vessels and lower portal pressure.

• Esophagogastric Balloon Tamponade: Uses specialized tubes (e.g., Sengstaken-Blakemore tube) with inflated balloons that press directly against the esophageal and gastric walls to compress bleeding vessels. Note: Balloon inflation must be carefully monitored, as excess pressure can potentially cause esophageal perforation or rupture.

• Endoscopic Procedures: Direct interventions such as endoscopic variceal ligation (banding) or sclerotherapy to isolate and stop active bleeding.

• TIPS Procedure (Transjugular Intrahepatic Portosystemic Shunt): Placement of a stent between the portal vein and hepatic vein to open portal blood flow and significantly reduce portal venous pressure

Pathophysiology

Esophageal varices are distended, fragile, thin-walled veins in the esophagus resulting from portal hypertension in cirrhosis. Blood meets resistance flowing through the diseased liver and seeks collateral venous channels, causing veins in the GI tract to become dilated and tortuous.

---

Clinical Presentation

Bleeding characteristics:

• Vomiting of blood (hematemesis) is the most common manifestation

• Usually develops slowly over years

• Acute rupture: Voluminous vomiting of dark-colored blood

• Usually painless

• Caused by combination of gastric acid erosion and increased venous pressure

Severity:

• Mortality: 30-60% from ruptured varices

• Recurrent bleeding indicates poor prognosis

• Can cause rapid blood loss requiring emergency intervention

---

Screening & Prevention

All cirrhosis patients screened by endoscopy to detect varices early before bleeding

Preventive therapy when varices detected:

• Nonselective beta-blockers (e.g., propranolol)

• Decreases heart rate and hepatic venous pressure gradient to reduce bleeding risk

• Monitor for bradycardia and hypotension

Antibiotic prophylaxis:

• 20% of cirrhosis patients with upper GI bleeding have bacterial infection on admission

• More develop healthcare-associated infections

• Infection is a common trigger for acute variceal bleeding

• Give antibiotics when admitted with GI bleeding

---

Acute Bleeding Management

Combination therapy:

• Vasoactive drugs + endoscopic procedures

Medications:

• Octreotide acetate: Reduces blood flow via vasoconstriction; suppresses gastrin, serotonin, and intestinal peptides to decrease GI blood flow

• Vasopressin: Rarely used due to potent adverse effects

Endoscopic procedures:

• Endoscopic variceal ligation (EVL): Small bands applied around varix base to decrease blood supply; patient unaware of bands

• Endoscopic sclerotherapy (EST): Sclerosing agent injected via catheter; risk of mucosal ulceration causing further bleeding

Rescue therapies if bleeding recurs:

• Second endoscopy

• Balloon tamponade with esophageal stents: Very effective but risks aspiration, asphyxia, esophageal perforation

• TIPS procedure (transjugular intrahepatic portal-systemic shunt)

What do I need to know about Cirrhosis and Hepatic Encephalopathy?

Hepatic encephalopathy is a major complication of cirrhosis that occurs primarily in end-stage liver disease.

---

1. Pathophysiology

• Portal Blood Shunting: Structural scarring and nodular tissue destroy normal liver architecture, resulting in the shunting of portal venous blood into central systemic circulation, completely bypassing the failing liver.

• Ammonia Toxicity: Because portal blood bypasses the liver, metabolic toxins—primarily ammonia generated by protein breakdown in the gut—accumulate in the bloodstream instead of being detoxified by hepatic cells. Elevated serum ammonia levels cross the blood-brain barrier, causing central nervous system toxicity and neuro-cognitive impairment.

---

2. Clinical Manifestations & Physical Assessment

• Altered Level of Consciousness (ALOC): Patients exhibit progressive neurological changes, including lethargy, confusion, somnolence, altered mental status, and impaired thought processes.

• Asterixis: A key characteristic physical finding marked by a coarse, flapping tremor of the hands and fingers.

• Fetor Hepaticus: A distinctive fruity or musty breath odor caused by the systemic accumulation of metabolic toxins excreted through the lungs.

• Laboratory Findings: Diagnostic evaluation reveals significantly elevated serum ammonia levels.

---

3. Medical & Nursing Interventions

The core focus of clinical management is lowering serum ammonia levels and suppressing ammonia production in the GI tract:

• Lactulose: Administered either orally or rectally. It acts as an osmotic laxative that promotes the intestinal excretion of ammonia, drawing ammonia into the colon to be purged through stool.

• Antibiotic Therapy: Medications such as Neomycin sulfate or Metronidazole (Flagyl) are prescribed to reduce the population of ammonia-producing bacteria in the small intestine.

• Nutrition Therapy: Implement simple, tailored dietary guidelines to manage protein breakdown while maintaining adequate nutrition without exacerbating ammonia buildup

Definition & Pathophysiology

Hepatic encephalopathy (also called portal-systemic encephalopathy) is a complex cognitive syndrome caused by liver failure and cirrhosis.

Mechanism:

• Liver dysfunction and collateral vessels shunt blood around the liver to systemic circulation

• Toxins absorbed from the GI tract normally removed by the liver accumulate and circulate freely to the brain

• Ammonia (from intestinal protein digestion) cannot be converted to urea by the diseased liver

• Accumulated toxins alter cerebral energy metabolism and interfere with neurotransmission

• Blood-brain barrier disruption causes edema, astrocyte swelling, and intracranial hypertension

Precipitating factors:

• Infection, systemic inflammation

• Hemorrhage, electrolyte imbalances (including zinc deficiency)

• Constipation

• Sedatives and analgesics

---

Clinical Manifestations

Four progressive stages:

Early symptoms:

• Sleep disturbances, mood disturbances

• Mental status changes, speech problems

• Subtle personality changes, memory loss

• Irritability, disinhibition, lethargy

Later symptoms:

• Altered level of consciousness

• Impaired thinking processes

• Confusion, disorientation to time and space

• Asterixis (flapping tremor of hands)

• Slow speech, bradykinesia

• Stupor, convulsions, coma

Note: Symptoms may gradually progress or fluctuate among stages. May develop slowly in chronic disease or rapidly in acute liver dysfunction. Reversible with early intervention.

---

Diagnosis & Monitoring

• History of liver disease + clinical manifestations + psychometric tests

• Exclusion of other causes of brain dysfunction

• Serum ammonia levels: Can assess treatment effectiveness but not a clear indicator

  • Some patients have major impairment without high ammonia

  • Ammonia elevations can occur without encephalopathy

---

Treatment

First steps:

• Correct fluid/electrolyte imbalances

• Withdraw depressant drugs metabolized by liver

• Limit opioids, sedatives, barbiturates

Nutrition:

• Moderate protein maintained to prevent malnutrition but controlled to reduce ammonia

• High-carbohydrate, moderate-fat diet

• Strict protein restrictions NOT required

Medications:

• Lactulose or polyethylene glycol: Reduce ammonia levels

• Rifaximin: Nonabsorbable antibiotic decreasing intestinal ammonia production; may combine with lactulose

• Neomycin: Eliminates ammonia-producing bacteria but nephrotoxic

• Glutamase inhibitors: Reduce gut ammonia

Advanced therapy:

• Extracorporeal liver support systems remove toxins

• Bridge to liver transplantation

What do I need to know about Cirrhosis and Jaundice?

In late-stage cirrhosis, irreversible scarring and nodular liver tissue block bile ducts and disrupt normal hepatic architecture. Jaundice (yellowing of the skin) and scleral icterus (yellowing of the eyes) occur when damaged hepatocytes and obstructed bile channels can no longer properly metabolize or excrete bilirubin, causing serum bilirubin to accumulate in the bloodstream.

---

1. Associated Cutaneous (Skin) Findings

Along with jaundice and icterus, late-stage cirrhosis leads to several characteristic skin manifestations:

• Pruritus (Severe Itching): Caused by bile salt accumulation in cutaneous tissues.

• Spider Angiomas: Small, vascular spider-like lesions visible on the skin.

• Palmar Erythema: Warm, bright red discoloration on the palms of the hands.

• Petechiae & Ecchymoses: Bruising and small purpuric lesions resulting from low platelet counts (thrombocytopenia) and prolonged prothrombin time (PT).

• Dry Skin & Rashes: General skin dryness and non-specific dermatologic rashes.

• Peripheral Dependent Edema: Fluid retention in the lower extremities and sacral area.

---

2. Diagnostic Laboratory Assessment

• Serum Bilirubin & Urobilinogen: Elevated due to impaired hepatic processing and biliary obstruction.

• ALT & AST Enzymes: Elevated during active liver inflammation; ALT is more specific to liver tissue injury, whereas AST is also present in cardiac, muscle, kidney, and brain tissues.

• Alkaline Phosphatase: Elevated, signaling biliary tract obstruction.

• Lactate Dehydrogenase (LDH): Elevated due to ongoing hepatic cell destruction.

• Total Serum Protein & Albumin: Decreased because the failing liver can no longer synthesize adequate plasma proteins.

• Coagulation Profile & CBC: Prolonged Prothrombin Time (PT), low platelet count (thrombocytopenia), and decreased Hgb/Hct.

---

3. Nursing Priorities & Care

• Skin Care & Pruritus Control: Keep skin cool and well-moisturized, avoid hot baths or harsh soaps, and prevent skin breakdown from scratching.

• Bleeding Precautions: Handle the patient gently and assess skin routinely for new petechiae, ecchymoses, or bleeding due to impaired coagulation.

• Medication Precautions: Administer prescribed drugs sparingly to avoid placing additional metabolic demand on damaged liver tissue

Pathophysiology: Two Types of Jaundice in Cirrhosis

Hepatocellular jaundice:

• Liver cells cannot effectively excrete bilirubin

• Results in excessive circulating bilirubin levels

Intrahepatic obstructive jaundice:

• Edema, fibrosis, or scarring of hepatic bile channels and bile ducts

• Interferes with normal bile and bilirubin excretion

Both types manifest as yellowish skin discoloration and often cause pruritus (itching).

---

Clinical Manifestations

Appearance:

• Yellow discoloration typically appears first in the sclera of the eye

• Then progresses to the skin as bilirubin attaches to elastin

Associated symptoms:

• Pruritus (itching): From bilirubin accumulation in the skin irritating itch receptors

• Worsens in warmer conditions, early evening, and at night

• Dark urine: Conjugated bilirubin is water-soluble and appears in urine (urobilinogen)

• May darken several days before jaundice onset

• Light or clay-colored stools: From complete bile flow obstruction from liver to duodenum

• With partial obstruction, stools remain normal colored

---

Laboratory Findings

• Total serum bilirubin: Elevated

• Indirect (unconjugated) bilirubin: Increased due to failing liver's inability to excrete bilirubin

• Urine urobilinogen: Increased

• Fecal urobilinogen: Decreased with biliary tract obstruction

• Alkaline phosphatase and GGT: Increased with biliary obstruction

---

Managing Pruritus

Comfort measures:

• Avoid being too warm

• Moisturize skin regularly

• Avoid skin irritants

• Cool compresses

• Corticosteroid creams for temporary relief

Medication:

• Selective serotonin reuptake inhibitors (e.g., sertraline) if comfort measures ineffective

---

Underlying Cause: Biliary Obstruction

Decreased vitamin K absorption:

• Cirrhosis decreases liver bile production

• Prevents absorption of fat-soluble vitamins including vitamin K

• Without vitamin K, clotting factors II, VII, IX, X not produced sufficiently

• Patient susceptible to bleeding and easy bruising

What do I need to know about Cirrhosis and Recent Lab values?

Laboratory Assessment Findings in Cirrhosis

• Liver Enzymes & Cell Injury Markers:

  • ALT (Alanine Aminotransferase) & AST (Aspartate Aminotransferase): Elevated during active hepatic inflammation. ALT is more specific to liver tissue injury, whereas AST is also found in cardiac, skeletal muscle, kidney, and brain tissues.

  • Lactate Dehydrogenase (LDH): Elevated due to ongoing hepatic cell destruction.

  • Alkaline Phosphatase: Elevated, signaling biliary tract obstruction.

• Bilirubin & Serum Proteins:

  • Total Serum Bilirubin & Urobilinogen: Elevated due to impaired hepatic metabolism and biliary obstruction, resulting in clinical jaundice and scleral icterus.

  • Total Serum Protein & Albumin: Decreased because the failing liver can no longer synthesize adequate plasma proteins, directly contributing to ascites and peripheral edema.

• Coagulation Profile & Complete Blood Count (CBC):

  • Prothrombin Time (PT): Prolonged due to impaired synthesis of hepatic clotting factors, significantly elevating bleeding risks.

  • Platelet Count (Thrombocytopenia): Low due to platelet trapping and destruction in an enlarged spleen (splenomegaly).

  • Hemoglobin & Hematocrit (Hgb/Hct): Decreased, reflecting anemia or gastrointestinal bleeding from esophageal varices.

  • White Blood Cell (WBC) Count: Decreased.

• Metabolic Toxins & Renal Markers:

  • Serum Ammonia: Elevated because portal venous blood is shunted past the failing liver, causing metabolic toxins from intestinal protein breakdown to accumulate and trigger hepatic encephalopathy.

  • Serum Creatinine: Possibly elevated, indicating secondary renal impairment or hepatorenal syndrome

Lab Value Ranges

1. Liver Enzymes

• ALT (Alanine Aminotransferase): 4–36 U/L (or 10–40 U/L)

  • Clinical Context: Elevated during hepatic inflammation; ALT is more specific to liver tissue injury than AST.

• AST (Aspartate Aminotransferase): 10–40 U/L (or 0–35 U/L)

  • Clinical Context: Elevated during hepatic inflammation, but also found in cardiac, skeletal muscle, kidney, and brain tissues.

---

2. Bilirubin & Serum Proteins

• Total Bilirubin: 0.3–1.2 mg/dL

  • Clinical Context: Elevated in liver dysfunction or biliary obstruction, leading to clinical jaundice and scleral icterus.

• Total Protein: 6.4–8.3 g/dL (Albumin component: 3.5–5.0 g/dL)

  • Clinical Context: Decreased in liver failure/cirrhosis because damaged hepatocytes can no longer synthesize adequate plasma proteins, directly contributing to ascites and peripheral edema.

---

3. Coagulation & Complete Blood Count (CBC)

• Prothrombin Time (PT): 11–12.5 seconds (INR: 0.8–1.1)

  • Clinical Context: Prolonged in hepatic disease due to impaired synthesis of clotting factors, significantly elevating bleeding risks.

• Platelet Count: 150,000–400,000 /mm³

  • Clinical Context: Decreased (thrombocytopenia) in cirrhosis due to platelet trapping and destruction within an enlarged spleen (splenomegaly).

• Hemoglobin (Hgb) & Hematocrit (Hct):

  • Hemoglobin (Hgb): Males 14–18 g/dL | Females 12–16 g/dL

  • Hematocrit (Hct): Males 42–52% | Females 37–47%

  • Clinical Context: Decreased in liver disease due to anemia and GI bleeding from esophageal varices, as well as in Chronic Kidney Disease (CKD) due to reduced renal synthesis of erythropoietin

Hepatic Enzymes

AST & ALT:

• Elevated during hepatic inflammation as enzymes release into blood

• ALT more liver-specific; AST found in muscle, kidney, brain, heart

• AST/ALT ratio >1.0: Typical in alcoholic liver disease

• May be normal in advanced disease when hepatocytes cannot mount inflammatory response

Alkaline phosphatase & GGT:

• Increased with biliary obstruction

• Alkaline phosphatase is nonspecific (bone, intestinal, liver enzyme)

---

Bilirubin

• Total serum bilirubin: Elevated

• Indirect bilirubin: Increased from failing liver's inability to excrete bilirubin

• Urine urobilinogen: Increased amounts

• Fecal urobilinogen: Decreased with biliary tract obstruction; light/clay-colored stools

---

Protein & Coagulation

Albumin:

• Decreased in severe/chronic liver disease from reduced hepatic synthesis

• Loss of osmotic "pull" promotes fluid shift into interstitial tissues (ascites)

Coagulation factors:

• PT/INR prolonged: Liver decreases prothrombin production

• Factor VII decreases first after liver damage (rapid turnover)

• Factor IX less affected until advanced liver destruction

• Most clotting factors significantly decreased in severe cirrhosis

• Clotting regulators (antithrombin, protein C, protein S) also diminished

---

Blood Cells

Platelets:

• Thrombocytopenia: Low platelet count characteristic of cirrhosis

• Decreased thrombopoietin production contributes to low platelets

RBCs:

• Anemia: Decreased RBC, hemoglobin, hematocrit values

WBCs:

• May be decreased

---

Other Values

• Ammonia: Usually elevated in advanced liver disease

• Serum creatinine: May be elevated with deteriorating kidney function

Renal Disorders

What is Acute Kidney Injury Prerenal?

Prerenal Acute Kidney Injury (AKI), also referred to as prerenal azotemia, is an acute reduction in kidney function caused by factors occurring outside the kidneys that severely restrict renal blood flow and perfusion.

---

1. Pathophysiology & Etiology

• Mechanism: Prerenal AKI occurs when systemic circulation is compromised, reducing blood flow to otherwise healthy kidney structures. If hypoperfusion is prolonged, prerenal AKI can progress to structural intrarenal tissue damage.

• Azotemia: The decrease in glomerular filtration leads to azotemia, which is the accumulation of nitrogenous waste products (BUN and Serum Creatinine) in the bloodstream.

• Common Causes:

  • Hypovolemia & Fluid Loss: Massive blood loss or trauma (e.g., severe hemorrhage from accidents or lacerations), severe dehydration from gastroenteritis (persistent vomiting and diarrhea), or fluid depletion.

  • Cardiovascular Failure: Myocardial infarction (heart attack) or heart failure, which reduces cardiac output and systemic circulating blood volume.

  • Shock: Hypovolemic or hypotensive shock leading to severe renal hypoperfusion.

---

2. Clinical Manifestations & Diagnostic Findings

• Oliguria / Decreased Urine Output: Urine production drops below the normal baseline of 30 mL/hr (or < 400 mL/day).

• Hemodynamic Changes: Hypotension (low blood pressure) and tachycardia triggered by volume depletion and poor perfusion.

• Weight Changes: Rapid loss of body weight secondary to severe fluid depletion.

• Lab Disturbances: Elevated Serum Creatinine and BUN, along with a significantly reduced Glomerular Filtration Rate (GFR).

---

3. Reversibility & Nursing Priorities

• Reversibility: Prerenal AKI is potentially reversible if the underlying cause is identified and treated quickly to restore adequate renal blood flow.

• Monitoring Output & Perfusion: Continuously assess hourly urine output (flag output < 30 mL/hr) and monitor daily weights and vital signs.

• Fluid Resuscitation: Administer prescribed IV fluids and rehydration therapy to restore circulating volume and renal blood flow.

• Nephrotoxic Precautions: Screen for and avoid nephrotoxic medications (e.g., Vancomycin) and IV radiopaque contrast dye (especially if baseline Creatinine is > 1.2 mg/dL) to prevent converting prerenal hypoperfusion into intrarenal kidney damage

Definition & Cause

Prerenal AKI is caused by conditions outside the kidney that impair renal perfusion. Common causes include shock, dehydration, burns, and sepsis.

---

Pathophysiology

When kidney perfusion decreases, the kidney compensates with three responses:

1. Constricting kidney blood vessels

2. Activating renin-angiotensin-aldosterone pathway

3. Releasing antidiuretic hormone (ADH)

These responses increase blood volume and improve kidney perfusion but reduce urine elimination, resulting in:

• Oliguria: Urine output <400 mL/day

• Azotemia: Retention and buildup of nitrogenous wastes in blood

---

Risk Factors

• Shock, cardiac surgery, hypotension

• Prolonged mechanical ventilation, sepsis

• Dehydration from burns, extensive bowel prep, or being NPO before surgery

• Recent IV vasopressor use (epinephrine, norepinephrine) with hypovolemia

---

Clinical Assessment

Anticipate AKI following any hypotensive episode or shock. Problems depleting blood volume contribute to AKI by reducing perfusion, including:

• Cardiac bypass surgery

• Extensive bowel preparations

• Being NPO before surgery

• Dehydration from exercise

---

Prevention & Management

Primary goal: Avoid hypotension and maintain normal fluid balance (euvolemia).

Blood pressure targets:

• Maintaining MAP of 80-85 mm Hg lowers AKI rates in patients with preexisting hypertension

• However, this increases atrial fibrillation risk compared to MAP 65-70 mm Hg

• Blood pressure goals determined by preexisting conditions and individual risk-benefit analysis

Key principle: Prevention is the most important therapeutic approach, involving avoidance of hypotension, hypovolemia, and nephrotoxicity.

---

Prognosis

Prerenal AKI is potentially reversible if perfusion is restored before intrarenal damage occurs. However, failure to restore blood volume, blood pressure, or oxygen delivery can cause ischemic cell injury and progress to acute tubular necrosis (ATN), a more severe intrarenal AKI

What is Acute Kidney Injury Intrarenal?

Intrarenal Acute Kidney Injury (AKI)—also known as intrinsic kidney injury—involves direct structural damage to the inside of the kidney, including the glomeruli, renal tubules, or interstitial tissue.

---

1. Primary Causes & Pathophysiology

Unlike prerenal or postrenal AKI, intrarenal injury results from direct pathology within the renal parenchyma:

• Nephrotoxic Substances: Medications and diagnostic agents that cause direct tubular damage, such as Vancomycin and IV radiopaque contrast dye (especially in patients with baseline serum creatinine > 1.2 mg/dL).

• Glomerular & Microvascular Damage: Pathologies affecting the filtering units, including Acute Glomerulonephritis and microvascular complications from Diabetes Mellitus.

• Acute Tubular Necrosis (ATN): Cell necrosis within the renal tubules resulting from severe ischemia, toxic injury, or donor organ hypoxia during transplantation.

• Inherited Tissue Disorders: Diseases like Polycystic Kidney Disease (PKD), where enlarging fluid-filled cysts damage neighboring nephrons and kidney tissue.

• Secondary Progression: Prolonged, untreated Prerenal hypoperfusion or severe Postrenal urinary obstruction (e.g., hydronephrosis) that leads to nephron death and converts into internal tissue damage.

---

2. Key Clinical Manifestations & Diagnostics

• Azotemia: A rapid accumulation of nitrogenous waste products in the blood, resulting in elevated Serum Creatinine and BUN.

• Oliguria or Anuria: A significant drop in urine production below the standard minimum baseline of 30 mL/hr (or < 400 mL/day during the oliguric phase).

• Declining GFR: A marked reduction in Glomerular Filtration Rate (GFR).

• Electrolyte Imbalances: High risk for hyperkalemia (elevated potassium) and fluid volume overload due to impaired excretion.

---

3. Phases of AKI & Reversibility

With prompt clinical intervention, intrarenal AKI may be reversible as the kidneys move through four distinct phases:

1. Onset Phase: Precipitating ischemic, toxic, or inflammatory event occurs.

2. Oliguric Phase: Urine output drops (< 30 mL/hr) with rising waste products and electrolyte imbalances.

3. Diuretic Phase: Renal clearance resumes with a surge in urine output (typically 2 to 6 weeks post-injury).

4. Recovery Phase: Complete restoration of renal function, which can take up to 12 months.

---

4. Essential Nursing Priorities

• Avoid Nephrotoxins: Screen medication lists carefully and advocate against administering IV contrast dye or nephrotoxic antibiotics if renal impairment is present.

• Monitor Urine Output & Labs: Closely monitor hourly output (flag output < 30 mL/hr) and track daily trends in Serum Creatinine, BUN, GFR, and potassium.

• Manage Fluid Balance: Assess for fluid overload (edema, pulmonary crackles) and weigh the patient daily

Definition & Classification

Intrarenal (intrinsic) AKI results from damage to kidney structures themselves—vascular, microvascular, glomerular, or tubulointerstitial. The most common cause is acute tubular necrosis (ATN).

---

Two Types of ATN

Ischemic ATN:

• Occurs after surgery, sepsis, obstetric complications, severe hemorrhagic trauma, or burns

• Hypotension and hypovolemia produce ischemia and inflammatory response

• Toxic oxygen free radicals cause cellular swelling, injury, and necrosis

• Intrarenal vasoconstriction decreases blood flow

• Necrosis is patchy and distributed along any part of the nephron

Nephrotoxic ATN:

• Associated with radiocontrast media and antibiotics, particularly aminoglycosides (neomycin, gentamicin, tobramycin) that accumulate in renal cortex

• Other nephrotoxins: myoglobin (crush injuries), heavy metals (mercury, arsenic), bacterial toxins

• Risk factors: Dehydration, advanced age, preexisting renal insufficiency, diabetes mellitus

• Necrosis is uniform and limited to proximal tubules due to high brush border surface area and reabsorptive properties

---

Pathophysiology

Tubular damage cascade:

• Renal tubular injury (necrosis, apoptosis) → cast formation

• Casts cause intratubular obstruction → increased intratubular pressure

• Tubular back leak → decreased GFR → oliguria

• Release of inflammatory mediators and vascular endothelial injury

• Renal vasoconstriction → persistent medullary hypoxia → further tubular injury

Systemic effects:

• Inflammatory proteins and immune complexes damage kidney cells

• Tubular cells slough and nephrons lose repair ability

• Tubular debris and sediment appear in urine

---

Prevention

Critical when using nephrotoxic agents:

• Combining two or more nephrotoxic drugs dramatically increases AKI risk4

• Closely monitor BUN, creatinine, and drug peak/trough levels

• Withhold nephrotoxic medications (e.g., metformin) 24 hours before and after contrast media if possible

• Administer IV fluids before and after contrast exposure

---

Prognosis

With severe AKI (stage 2 or 3), some patients return to baseline kidney function during recovery. However, extensive damage may prevent nephron self-repair

What is Acute Kidney Injury Postrenal?

Postrenal Acute Kidney Injury (AKI) occurs when a mechanical obstruction below the kidneys blocks the outflow of urine from the body.

---

1. Pathophysiology & Causes

• Mechanism: When urine flow is obstructed in the ureters, bladder, or urethra, urine backs up into the renal pelvis and kidney structures.

• Common Precipitating Factors:

  • Urinary Tract Calculi (Stones): Nephrolithiasis or ureterolithiasis obstructing the ureter or bladder neck.

  • Benign Prostatic Hyperplasia (BPH): Prostate enlargement in older adult men compressing the urethra.

  • Urethral Strictures & Scarring: Narrowed areas of the ureter or urethra due to scar tissue or previous trauma/infection.

  • Tumors or Pelvic Masses: External structural compression on the urinary tract.

---

2. Critical Complication: Hydronephrosis

• Hydronephrosis & Hydroureter: Obstruction causes the ureter (hydroureter) and the kidney (hydronephrosis) to enlarge and distend with backed-up urine.

• Progression to Intrarenal AKI: If the obstruction is not relieved promptly, the increased pressure within the kidney causes nephron death and structural parenchymal damage—effectively converting postrenal AKI into intrarenal kidney injury.

---

3. Clinical Manifestations & Diagnostics

• Urinary Output Changes: Marked decrease in urine output (oliguria <30 mL/hr) or complete absence of urine (anuria).

• Pain: Flank pain, abdominal pain, or severe renal colic radiating toward the groin (especially with kidney stones).

• Bladder Symptoms: Bladder distention, fullness, or overflow incontinence if the obstruction is lower in the urinary tract.

• Diagnostics:

  • Renal Ultrasound, CT Scan, or IV Urography: Preferred imaging to visualize urinary tract dilation and locate the blockage.

  • Laboratory Markers: Elevated Serum Creatinine and BUN (postrenal azotemia) reflecting waste accumulation.

---

4. Medical & Nursing Interventions

• Relieve the Obstruction: The primary goal of treatment is to quickly remove or bypass the blockage to prevent permanent kidney damage.

• Drainage Procedures:

  • Placement of a urinary catheter or ureteral stent to bypass ureteral/urethral strictures.

  • Nephrostomy Tube: Placement of a surgical drain directly into the renal pelvis if lower catheterization is impossible.

• Surgical & Stone Management: Lithotripsy or surgical stone removal (e.g., ureterolithotomy) for obstructive stones.

• Post-Unblocking Monitoring: Monitor hourly urine output closely once the obstruction is relieved (watching for post-obstructive diuresis and electrolyte imbalances) and track the recovery of BUN and Creatinine

Definition & Cause

Postrenal AKI is caused by obstruction of urine flow 2. The obstruction must affect the kidneys bilaterally (e.g., bladder outlet obstruction, prostatic hypertrophy, bilateral ureteral obstruction), or involve a tumor or neurogenic bladder 1.

---

Common Causes

• Tumors

• Kidney stones

• Strictures

• Bladder outlet obstruction

• Prostatic hypertrophy

---

Pathophysiology

Mechanism:

• Obstruction causes increased intraluminal hydrostatic pressure upstream from blockage site

• Results in gradual decrease in GFR

Compensatory response:

• Kidney constricts blood vessels, activates renin-angiotensin-aldosterone pathway, and releases ADH

• These responses increase blood volume and improve perfusion but reduce urine elimination

• Results in oliguria (urine output <400 mL/day) and azotemia

---

Classic Presentation

Characteristic pattern: Several hours of anuria (urine output <50 mL/day) with flank pain followed by polyuria

---

Clinical Assessment

History to obtain:

• Any difficulty starting urine stream

• Changes in urine amount or appearance

• Narrowing of urine stream

• Nocturia, urgency

• Symptoms of kidney stones

• Cancer history that may cause urinary obstruction

---

Prevention

Key principle: Prevention is the most important therapeutic approach, involving avoidance of hypotension, hypovolemia, and nephrotoxicity.

---

Prognosis

Postrenal AKI is potentially reversible if obstruction is relieved promptly. With prerenal or postrenal pathology, kidney compensatory mechanisms can restore function if the underlying cause is addressed

What is Chronic Kidney Disease?

Chronic Kidney Disease (CKD) is defined as progressive, irreversible kidney injury where kidney function does not recover over time12. As nephrons are destroyed, waste products accumulate in the bloodstream (azotemia), leading to systemic uremic syndrome1more_horiz.

---

1. Stages of CKD (Based on Glomerular Filtration Rate - GFR)

• Stage I (At Risk): Reduced renal reserve with normal filtering capacity; GFR > 90 mL/min14.

• Stage II (Mild CKD): Slight nephron damage and mild elevation of metabolic waste; GFR = 60–89 mL/min14.

• Stage III (Moderate CKD): Continued nephron loss with rising BUN and Serum Creatinine; requires restriction of fluids, electrolytes, and protein; GFR = 30–59 mL/min.

• Stage IV (Severe CKD): Severe nephron damage; focus shifts to managing complications and preparing for renal replacement therapy (dialysis or kidney transplantation); GFR = 15–29 mL/min.

• Stage V (End-Stage Kidney Disease - ESKD): Severe fluid, electrolyte, and acid-base imbalances; fatal without renal replacement therapy; GFR < 15 mL/min.

---

2. Systemic & Laboratory Changes in CKD

• Metabolic Waste & Lab Trends:

  • BUN & Serum Creatinine: Continually elevate as urine output declines. Normal Serum Creatinine is ~0.5–1.2 mg/dL.

  • Potassium (K^+): Hyperkalemia occurs in chronic/late CKD due to impaired renal excretion, creating a life-threatening risk for cardiac dysrhythmias.

  • Calcium (Ca^+2) & Phosphorus (Phos): Possess an inverse relationship — Hyperphosphatemia develops because the kidneys cannot excrete phosphorus, which in turn causes Hypocalcemia by pulling calcium out of the bones57. This leads to renal osteodystrophy (bone pathology visible on X-rays).

  • Acid-Base Balance: Results in metabolic acidosis due to impaired excretion of hydrogen ions and reabsorption of bicarbonate.

• Cardiovascular & Respiratory Changes:

  • Complications include hypertension, hyperlipidemia, heart failure, and pericarditis.

  • Inability to excrete water leads to fluid volume overload, causing peripheral edema and pulmonary crackles in the lungs.

• Hematologic Changes:

  • Anemia: Diseased kidneys produce less erythropoietin, leading to decreased red blood cell synthesis and reduced Hemoglobin/Hematocrit (Hgb/Hct).

• Gastrointestinal & Skin Manifestations:

  • Uremic Manifestations: Systemic accumulation of urea causes anorexia, nausea, vomiting, peptic ulcer disease, and uremic halitosis (foul/musty breath odor from waste excreted through mucous membranes).

  • Skin Findings: Severe itching (pruritus) and uremic frost (urea crystals depositing on the skin in severe end-stage uremia.

• Imaging Findings:

  • X-rays and ultrasounds demonstrate renal atrophy (small, shrunken kidneys because non-functioning nephrons shrink).

---

3. Priority Nursing Interventions & Management

• Dietary Restrictions: Teach patients to restrict Potassium, Phosphorus, Protein (to reduce nitrogenous waste/urea production), Sodium, and Fluids.

• Anemia Management: Administer prescribed recombinant human erythropoietin to stimulate red blood cell production.

• Fluid & Cardiac Monitoring: Assess for signs of fluid overload (weigh daily, track hourly urine output, monitor for pulmonary crackles, evaluate edema)1more_horiz. Elevate the head of the bed to relieve dyspnea.

• Avoid Nephrotoxins: Screen medication lists and advocate against administering nephrotoxic antibiotics (e.g., Vancomycin) or IV radiopaque contrast dye.

• Psychosocial Assessment: Assess coping mechanisms, anxiety, and support systems due to the lifestyle changes associated with chronic care and time-intensive dialysis schedules (typically 3 times per week for 3 hours)

Definition

Chronic Kidney Disease (CKD) is the progressive and irreversible loss of renal function indicated by a GFR <60 mL/min/1.73 m² for 3 months or longer, irrespective of cause.

---

Risk Factors & Causes

• Diabetes mellitus (most significant risk factor)

• Hypertension

• Systemic lupus erythematosus

• Acute kidney injury (AKI)

• Chronic glomerulonephritis

• Chronic pyelonephritis

• Obstructive uropathies

• Vascular disorders

---

Five Stages of CKD

Stage 1: GFR >90 mL/min/1.73 m²

• Normal GFR but abnormal urine findings, structural abnormalities, or genetic traits pointing to kidney disease

• Increased risk from infection, inflammation, pregnancy, dehydration, hypotension

Stage 2: GFR 60-89 mL/min/1.73 m²

• Nephron damage occurred; slight elevations of metabolic wastes

• Albuminuria may be present

• Increased output of dilute urine may lead to severe dehydration

Stage 3: GFR 30-59 mL/min/1.73 m² (divided into 3a and 3b at GFR <45)

• Greater nephron damage; azotemia (poor waste elimination) present

• Albuminuria usually present

• Requires restriction of fluids, proteins, and electrolytes

Stage 4: GFR 15-29 mL/min/1.73 m²

• Severe impairments in fluid, electrolyte, and acid-base balance

Stage 5 (ESKD): GFR <15 mL/min/1.73 m²

• End-stage kidney disease

• Excessive urea and creatinine buildup

• Without kidney replacement therapy, death results

---

Albuminuria Stages

• A1: <30 mg/g creatinine (none to mild)

• A2: 30-300 mg/g creatinine (moderate)

• A3: >300 mg/g creatinine (severe)

---

Key Lab Values

Monitor: creatinine, BUN, sodium, potassium, calcium, phosphorus, bicarbonate, hemoglobin, hematocrit, and GFR trends

Early CKD urinalysis may show protein, glucose, RBCs, WBCs, decreased/fixed specific gravity

Advanced CKD: Urine output decreases; osmolarity increases

---

Management

• Glycemic control and blood pressure management (ACE inhibitors/ARBs)

• Dietary restriction: protein, sodium, potassium, phosphate

• Vitamin D supplementation for hyperphosphatemia

• Erythropoietin for anemia

• SGLT2 inhibitors (nephroprotective in diabetic nephropathy)

What is Acute Glomerulonephritis?

Acute Glomerulonephritis is an immunologic kidney disorder and stands as the 3rd leading cause of end-stage kidney disease. It involves inflammation and structural damage to the glomeruli—the microvascular filtering units inside the kidneys—and is most frequently triggered by an infection.

---

1. Clinical Manifestations (Signs & Symptoms)

• Pink or Cola-Colored Urine: Resulting from hematuria (blood in the urine).

• Foamy Urine: Caused by proteinuria (protein leaking through damaged glomerular capillaries).

• Edema: Occurs in approximately 75% of patients, commonly appearing in the hands, face, and abdomen.

• Hypertension: Elevated blood pressure resulting from impaired sodium and fluid clearance.

---

2. Diagnostic Assessment

• Urinalysis & 24-Hour Urine Collection: Used to quantify protein loss and assess cellular components in urine.

• Renal Imaging: X-rays, CT scans, and renal ultrasounds to evaluate kidney structures.

• Kidney Biopsy: The key definitive diagnostic procedure performed percutaneously to determine the precise cause of unexplained renal pathology.

---

3. Medical & Nursing Interventions

• Infection Control: Effectively managing and treating the underlying infectious process.

• Fluid & Blood Pressure Management: Interventions aimed at controlling fluid volume overload and strictly managing hypertension to prevent further renal injury.

• Renal Replacement: Dialysis may be required if renal function declines significantly

Definition

Acute Glomerulonephritis (GN) is a condition that develops suddenly from an excessive immune response within the kidney tissues 1. It's a group of diseases that injure and inflame the glomerulus (the part of the kidney that filters blood).

---

Pathophysiology

Mechanism:

• Develops with deposition of antigen-antibody complexes in the glomerulus

• Complexes activate complement and release inflammatory mediators

• Recruits neutrophils, lymphocytes, and macrophages

• Damages glomerular basement membrane → alters permeability

• Results in decreased GFR with sodium and fluid retention, hematuria, and proteinuria

---

Causes

Primary GN: Many causes are infectious

Most common form in children: Acute Poststreptococcal GN (PSGN)

• Caused by nephritogenic strains of Streptococcus pyogenes (group A β-hemolytic Strep)

• Symptoms begin 1-2 weeks after upper respiratory infection (pharyngitis) or up to 6 weeks after skin infection (impetigo)

Other causes 2: Bacterial endocarditis, staphylococcal infections, viral diseases (varicella-zoster, hepatitis B and C)

Secondary GN: Caused by multisystem diseases

---

Classic Onset Pattern

Usually an infection is noticed before kidney symptoms appear. Onset of symptoms is about 10 days from time of infection.

---

Clinical Manifestations

Urine changes:

• Hematuria with red blood cell casts

• Blood described as smoky, reddish brown, rusty, or cola-colored4

• Proteinuria (may exceed 3-5 g/day)

• Oliguria (urine output ≤400 mL/24 hr)

Systemic signs:

• Edema (face, eyelids, hands)

• Hypertension (mild to moderate)

• Fluid overload, pulmonary edema

• Fatigue, anorexia, nausea/vomiting if uremia present

---

Laboratory Findings

• Hematuria and proteinuria on urinalysis

• Red blood cell casts on microscopic exam

• Protein excretion: 500 mg/24 hr to 3 g/24 hr

• Decreased serum albumin

• Elevated creatinine and BUN

• Decreased GFR (may be ~50 mL/min)

---

Prognosis

Patients usually recover quickly and completely from acute GN

What is Polycystic Kidney Disease?

Polycystic Kidney Disease (PKD) is an inherited genetic disorder characterized by the development and progressive enlargement of fluid-filled cysts within the nephrons As these cysts expand and multiply, they compress and destroy surrounding nephron tissue, causing a gradual loss of kidney function. Beyond the renal system, cysts can also form in other organs and vascular structures, particularly the liver and blood vessels.

---

1. Clinical Manifestations (Signs & Symptoms)

• Hypertension: High blood pressure develops in the vast majority of patients with PKD.

• Abdominal & Flank Pain: Caused by expanding cysts creating pressure on surrounding retroperitoneal tissues.

• Distended Abdomen: Visible abdominal enlargement resulting from massively enlarged, cyst-filled kidneys.

• Urinary Changes: Patients frequently present with bloody urine (hematuria) and proteinuria.

• Nocturia: Nighttime voiding is a characteristic early sign and symptom of PKD.

---

2. Diagnostic Evaluation

• Urinalysis: Detects the presence of blood (hematuria) and protein (proteinuria) leaking into the urine.

• Renal Imaging: Confirmed using renal sonography (ultrasound), CT scans, or MRI to visualize cyst distribution and structural organ changes.

---

3. Nursing Priorities & Interventions

• Hypertension Control:

  • Maintain hydration with adequate fluid intake to avoid dehydration.

  • Enforce dietary sodium restrictions.

  • Administer prescribed antihypertensive medications—specifically ACE inhibitors, which can also help control cyst cell growth.

• Pain Management:

  • Use NSAIDs with caution, as they may reduce renal blood flow.

  • Avoid aspirin due to bleeding risks.

  • Administer antibiotics promptly if an underlying infectious process is present.

  • Incorporate non-pharmacological pain relief methods.

• Preventing Constipation: Promote fluid intake, dietary fiber, and exercise to prevent constipation, which can exacerbate abdominal discomfort from enlarged kidneys.

• Patient Education & Support: Refer patients to resources such as the National Polycystic Kidney Disease Foundation.

---

4. Transplantation Consideration

• Unlike most other end-stage kidney diseases where non-functioning kidneys are left in place during a transplant, PKD kidneys may need to be surgically removed if they grow so large that they run out of space in the abdominal cavity

Definition

Polycystic Kidney Disease (PKD) is an inherited condition where affected kidneys have multiple cysts that interfere with renal function. It occurs in about 1 in 1,000 to 2,500 live births.

---

Genetics

PKD is associated with mutation of two genes that regulate processes like fluid transport:

• PKD1 (autosomal dominant, chromosome 16) - most common

• PKD2 (autosomal recessive, chromosome 4) - rarer

Autosomal dominant PKD (ADPKD) is the most common inherited kidney disease, occurring in 1 in 1,000 live births. Rarely, a new gene mutation can cause PKD with no family history, but these tend to be milder forms.

---

Pathophysiology

Defects in epithelial cells and their cilia result in cyst formation in all parts of the nephron. Cysts can also develop in other organs including the liver, pancreas, and ovaries.

---

Complications

• Hypertension

• Aortic and intracranial aneurysms

• Heart valve defects

---

Clinical Presentation

Pain is often the first symptom.

Physical findings:

• Distended abdomen as cystic kidneys swell

• Enlarged, palpable kidneys (use gentle palpation as they may be tender)

• Flank pain: Dull ache (from kidney distention or infection) or sharp/intermittent (from cyst rupture or stones)

• Hematuria: Bright red or cola-colored urine when cyst ruptures

• Cloudy/foul-smelling urine or dysuria suggests infection

Urinary symptoms:

• Nocturia (early symptom from decreased concentrating ability)

• Early PKD: Hyperfiltration → sodium and water wasting

• Late PKD: Reduced GFR → sodium/water retention → hypertension, edema, uremic symptoms (anorexia, nausea, vomiting, pruritus, fatigue)

---

Diagnosis

• Ultrasound: Primary diagnostic method to measure kidney size and identify cysts

• MRI or CT: Confirm ultrasound findings; provide quantitative data on tissue oxygenation, fibrosis, edema, inflammation, perfusion

• Urinalysis: Proteinuria (declining function), hematuria, bacteria (infection)

• Labs: Rising BUN and creatinine; decreased creatinine clearance and GFR

---

Prognosis & Management

PKD is often first suspected on prenatal ultrasound. Renal replacement therapy is usually required during childhood or adolescence. There is no way to prevent PKD, though early detection and management of hypertension may slow progression

Urinary Disorders

What are UTIs?

1. Anatomical Classification of UTIs

Urinary tract infections are categorized based on where the infection is located within the urinary system:

• Cystitis: Infection/inflammation of the bladder (lower UTI).

• Urethritis: Infection of the urethra.

• Prostatitis: Infection of the prostate gland in males.

• Pyelonephritis: Bacterial infection of the kidney pelvis and parenchyma (upper UTI).

---

2. Clinical Manifestations of Cystitis (Lower UTI)

• Classic Symptoms: Increased urinary frequency, sudden urgency, and dysuria (pain or burning during urination).

• Urine Characteristics: Urine appears cloudy, blood-tinged, and foul-smelling.

• Systemic Signs: Low-grade fever and leukocytosis (elevated WBC count).

• Older Adult Considerations: Older patients frequently do not present with typical localized symptoms like dysuria; instead, a UTI often manifests as sudden confusion, altered level of consciousness, functional decline, or new/worsening incontinence.

---

3. Diagnostic Evaluation

• Urinalysis (UA): Used for primary screening; collecting the first morning void provides the most accurate sample.

• Urine Culture & Sensitivity (C&S): Collected using the clean-catch method to isolate the specific causative organism and guide antibiotic selection.

---

4. Treatment & Nursing Priorities

• Pharmacologic Management: Administer prescribed antibiotic therapy tailored to the organism's sensitivity.

• Hydration & Nutrition: Promote a well-balanced diet and encourage adequate fluid intake to help flush bacteria from the urinary tract.

• Comfort Measures: Provide sitz baths to relieve local perineal discomfort.

---

5. Key Complication: Ascent to Pyelonephritis

• If lower urinary tract infections are left untreated, bacteria can migrate upward into the renal pelvis, resulting in Acute Pyelonephritis, which presents with high fever, chills, tachycardia, and severe costovertebral angle (CVA) / flank pain

Definition

UTI = invasion of the urinary tract by an infectious organism

• Acute UTI: Single occurrence

• Recurrent UTI: ≥2 infections in 6 months OR ≥3 infections in 1 year

---

Types

Uncomplicated UTI:

• No anatomic/functional abnormalities

• No conditions increasing infection risk or treatment failure

Complicated UTI:

• Requires longer antimicrobial treatment and greater vigilance

• Risk factors: Pregnancy, male sex, obstruction, diabetes, neurogenic bladder, chronic kidney disease, reduced immunity

---

Classic Symptoms

Hallmark triad:

• Frequency: Urge to urinate frequently in small amounts

• Dysuria: Pain or burning with urination

• Urgency: Feeling that urination will occur immediately

Additional signs:

• Cloudy, foul-smelling, or blood-tinged urine

• Fever ± chills

• Suprapubic or flank pain

Catheterized patients: New hypotension or mental status changes (plus other UTI signs)

⚠ Older adults: Do not diagnose UTI based on mental status changes alone—UTI symptoms must be present

---

Assessment

• Ask patient to void before exam (for specimen and bladder palpation)

• Check vital signs (fever, tachycardia, tachypnea)

• Inspect lower abdomen and palpate bladder

• If catheter in place >2 weeks: Replace before obtaining culture specimen

---

Laboratory Diagnosis

Urinalysis:

• Positive leukocyte esterase + nitrates = 68-88% sensitive for UTI

• May show WBCs, RBCs, or casts

Urine culture 4: Indicated when:

• Complicated UTI present

• Patient doesn't respond to usual therapy

• Diagnosis uncertain

• Need to assess antibiotic sensitivity

---

Prevention

• Liberal fluid intake: 2.2 L (females), 3 L (males) OR enough for 1.5 L clear/light yellow urine daily

• Sterile technique for catheter insertion in health care facilities

• Minimize catheter use and duration

What is Acute Pyelonephritis?

Acute Pyelonephritis is an active bacterial infection of the kidney and renal pelvis. It triggers localized inflammation, tubular cell necrosis, and renal tissue edema.

---

1. Clinical Manifestations (Signs & Symptoms)

• Fever & Chills: Sudden onset of high fever accompanied by severe chills.

• Cardiopulmonary Changes: Tachycardia (increased heart rate) and tachypnea (increased respiratory rate).

• Localized Flank Pain: Severe back or flank pain situated at the costovertebral angle (CVA).

---

2. Diagnostic Evaluation

• Urinalysis: Detects leukocytes, bacteria, and signs of infection in the urine.

• Urine Culture & Sensitivity (C&S): Identifies the specific causative bacteria and guides targeted antibiotic selection.

• Renal Imaging: Imaging studies such as X-rays and Intravenous (IV) Urography are used to assess structural abnormalities or blockages.

---

3. Medical & Nursing Interventions

• Pharmacologic Management: Administer prescribed antibiotics to eradicate the bacterial infection alongside analgesics for pain relief.

• Nutrition & Hydration: Maintain a balanced diet and encourage adequate fluid intake to flush the urinary tract.

• Surgical Correction: Perform surgical interventions when necessary to remove obstructing stones or repair anatomical defects.

• Preventing Complications: Promote strict medication compliance and blood pressure control to prevent progression toward End-Stage Kidney Disease (ESKD).

---

4. Acute vs. Chronic Pyelonephritis

• Acute Pyelonephritis: An active, short-term bacterial infection.

• Chronic Pyelonephritis: Results from repeated UTIs or vesicoureteral reflux (urine backflow from the bladder into the ureters and kidneys). Chronic cases lead to renal scarring, hypertension, sodium-wasting, and nocturia

Definition

Acute Pyelonephritis is a complication of an ascending urinary tract infection that spreads from the bladder to the kidneys 1. It interferes with urinary elimination, which is the excretion of waste from the body by the urinary system.

---

Pathophysiology

Causative organisms:

• E. coli (most common)

• Proteus, Pseudomonas

• Enterococcus faecalis (hospitalized patients)

• Klebsiella species, Pseudomonas aeruginosa

Infection route: Typically ascending along the ureters; may also spread via bloodstream

Kidney damage:

• Inflammation primarily affects the pelvis, calyces, and medulla

• Infiltration of white blood cells → renal edema and purulent urine

• Tubules are primarily affected; glomeruli usually spared

• Severe infection → localized abscesses in medulla extending to cortex

• Healing occurs with fibrosis and atrophy of affected tubules

⚠ Severe complication: Emphysematous pyelonephritis (gas-forming pathogens, often E. coli) is life-threatening and requires nephrectomy

---

Risk Factors

• Urinary catheterization or tract manipulation

• Obstruction (stones, cancer, scarring)

• Reflux (bladder tumors, prostate enlargement, stones)

• Urinary stasis (prolonged bed rest, paralysis)

• Reduced immunity or diabetes

• Diabetic neuropathy, spinal cord injury, neurodegenerative diseases

• NSAIDs (high-dose or prolonged use) → papillary necrosis

---

Who's Affected

• Young, sexually active females most commonly affected

• Pregnant patients: Higher risk during 2nd trimester and early 3rd trimester due to hormonal changes and fetal obstruction

• Risk during pregnancy: Premature labor and delivery

---

Signs & Symptoms

Key features:

• Flank pain and costovertebral angle (CVA) tenderness

• Changes in urine color or odor

• Low-grade fevers (especially chronic pyelonephritis)

• Urinary symptoms or abdominal discomfort

Physical exam: Inspect flanks for enlargement, asymmetry, edema, or redness; gently palpate/percuss CVA for tenderness

What is Urolithiasis?

Urolithiasis refers to the presence of calculi (stones) within the urinary tract. Depending on the specific location of stone formation, it is classified as nephrolithiasis (stones in the kidney) or ureterolithiasis (stones in the ureter or bladder). Approximately 75% of all urinary stones are composed of calcium oxalate.

---

1. Clinical Manifestations (Signs & Symptoms)

• Renal Colic: Severe, sharp flank or back pain that can radiate around to the side and lower abdomen.

• Autonomic & Gastrointestinal Signs: Nausea, vomiting, pallor, and profuse diaphoresis.

• Urinary Symptoms: Frequency and dysuria; if the stone blocks urine outflow, it can cause oliguria (scant urine output) or anuria (no urine output).

---

2. Diagnostic Testing

• Laboratory Tests: Urinalysis (checking for hematuria and infection) and serum WBC counts.

• Imaging: KUB (Kidneys, Ureters, Bladder) X-rays, Intravenous Urography (IVP), CT scans, and renal ultrasounds to locate the stone and check for obstruction.

---

3. Medical & Nursing Interventions

• Straining Urine: Always strain all urine using a urine strainer to capture stone fragments for lab composition analysis.

• Pain Management: Administer prescribed opioids, NSAIDs, and antispasmodics, alongside non-pharmacological therapies.

• Extracorporeal Shock Wave Lithotripsy (ESWL):

  • Uses sound, laser, or dry shock wave energy under conscious sedation to break stones into small pieces.

  • Pre-Procedure Care: Ensure the patient stops taking medications that impair blood clotting (such as aspirin, ibuprofen, or warfarin), obtain informed consent, keep the patient NPO for several hours, and apply topical anesthetic cream 45 minutes prior to the procedure.

  • Intra- & Post-Procedure Care: Continuously monitor the patient via electrocardiography (ECG) during the procedure. Post-procedure, strain all urine and inspect the site.

• Surgical & Mechanical Management: Placement of a ureteral stent, cystoscopic stone extraction, nephrostomy tube placement, or open stone removal (e.g., ureterolithotomy or nephrolithotomy).

---

4. Nutritional Guidelines for Prevention (Calcium Oxalate Stones)

To prevent stone recurrence in patients with calcium oxalate stones:

• Hydration: Increase fluid consumption to 3 to 4 quarts daily (primarily water).

• Oxalate & Vitamin Restrictions: Avoid high-oxalate foods (nuts, beans, berries, tea, and chocolate) and avoid megadoses of Vitamin C.

• Protein & Sodium: Reduce high protein and high sodium intake.

• Calcium Intake: Maintain adequate, balanced calcium intake throughout the day (rather than restricting calcium)

Definition

Urolithiasis is the presence of calculi (stones) in the urinary tract. Stones often cause no symptoms until they pass into the lower urinary tract, where they can cause excruciating pain.

Related terms:

• Nephrolithiasis: Stone formation in the kidney

• Ureterolithiasis: Stone formation in the ureter

---

Pathophysiology

Stone formation occurs when particles in urine become supersaturated (concentration too high to stay dissolved), causing them to precipitate and collect into calculi.

Key mechanisms:

• Supersaturation: Higher concentration of salts than urine can dissolve

• Crystallization: Crystals grow from a small nucleus (nidus) to larger stones

• Matrix: Organic material (mucoprotein) in which stone components are embedded

• Randall plaque: Renal tubule/papillae surfaces that attract crystalline nidus

Note: Intermittent supersaturation (after meals or during dehydration) is sufficient for stone growth

---

Types of Stones

• Calcium oxalate or calcium phosphate: 70-80%

• Struvite (magnesium-ammonium-phosphate): 5-10%

• Uric acid: 5-10%

• Cystine: ≤2% (genetic predisposition)

Size classification:

• Staghorn calculi: Large stones filling minor and major calyces

• Nonstaghorn calculi: Variable size, smaller, located in calyces, pelvis, or ureter

---

Risk Factors

• Genetic predisposition

• Age, sex, race, geographic location

• Dehydration/low fluid intake

• Dietary patterns

• Inactivity

• UTI, hypertension, atherosclerosis, metabolic syndrome, obesity, type 2 diabetes

---

Signs & Symptoms

Pain:

• Renal colic: Sudden, "unbearable" pain

• Large stationary stones (staghorn): Rarely cause pain

• Often accompanied by nausea, vomiting, pallor, diaphoresis

Urinary symptoms:

• Frequency and dysuria when stone reaches bladder

• Oliguria or anuria: Suggests obstruction

• Hematuria: Urine appears smoky or rusty

Physical findings 5: Pallor, diaphoresis, excruciating pain, elevated vital signs (with infection), possible shock (low BP)

---

Diagnosis

• Urinalysis: Check specific gravity, pH, hematuria

• Urine pH: Low pH → uric acid/cystine stones; High pH → calcium phosphate/struvite stones

• 24-hour urine analysis: Assess supersaturation

Renal Diagnostics and Therapies

What do you know about Electrolytes, BUN, Creatinine, GFR in regards to renal diagnostics and therapies?

1. Serum Creatinine & Blood Urea Nitrogen (BUN)

• Serum Creatinine: Normal baseline is 0.5 – 1.2 mg/dL. Produced by muscle protein breakdown and excreted entirely by the kidneys, making it the most specific and reliable laboratory indicator of renal function.

• Blood Urea Nitrogen (BUN): Measures renal excretion of urea nitrogen generated from protein breakdown in the liver3. Suggestive of renal function, but non-renal factors like dehydration, high-protein intake, or tissue breakdown can also raise levels.

• Azotemia & Uremia: The systemic accumulation of nitrogenous waste products (elevated BUN and Creatinine) is termed azotemia. As waste levels rise in severe/end-stage renal failure, patients develop uremic syndrome (manifesting as anorexia, nausea, vomiting, uremic halitosis, and uremic frost).

---

2. Glomerular Filtration Rate (GFR)

• Definition: GFR reflects the total filtering capacity of nephrons, with a normal baseline around 100 mL/min (or > 90 mL/min).

• CKD Staging Based on GFR:

  • Stage I (At Risk): Reduced renal reserve; GFR > 90 mL/min.

  • Stage II (Mild CKD): Slight nephron damage and slight waste buildup; GFR = 60–89 mL/min.

  • Stage III (Moderate CKD): Continued nephron loss with rising BUN/Creatinine; requires restriction of fluids, electrolytes, and protein; GFR = 30–59 mL/min.

  • Stage IV (Severe CKD): Severe nephron loss; manage complications and prepare for renal replacement therapy (dialysis or kidney transplant); GFR = 15–29 mL/min.

  • Stage V (End-Stage Kidney Disease - ESKD): Severe fluid, electrolyte, and acid-base imbalances; fatal without dialysis or transplant; GFR < 15 mL/min.

---

3. Key Electrolyte Imbalances in Renal Failure

• Potassium (K^+):

  • Hyperkalemia develops in chronic/late kidney disease and the oliguric phase of AKI because damaged nephrons cannot excrete potassium.

  • Critical Priority: High potassium is the most dangerous electrolyte imbalance due to the risk of life-threatening cardiac dysrhythmias and cardiac arrest. It is a primary laboratory marker evaluated prior to dialysis.

• Sodium (Na^+):

  • May be low in early stages due to dilution or impaired reabsorption, but late renal failure leads to sodium and fluid retention, requiring dietary sodium and fluid restrictions.

• Calcium (Ca^2+) & Phosphorus (Phos):

  • Calcium and phosphorus maintain an inverse relationship.

  • Impaired renal excretion causes Hyperphosphatemia.

  • Elevated phosphorus pulls calcium from the bones, resulting in Hypocalcemia.

  • This bone mineral leaching causes renal osteodystrophy (visible on bone X-rays). Administer phosphate binders with meals to help manage phosphorus levels.

---

4. Diagnostic & Therapeutic Care Precautions

• IV Radiopaque Contrast Safety (e.g., IV Urography / CT Scans):

  • IV contrast dye is nephrotoxic and can trigger or worsen acute kidney damage.

  • Nursing Priority: Check baseline BUN and Creatinine prior to procedures (contrast is typically held if baseline Creatinine is > 1.2 mg/dL)1819. Hydrate the patient with IV fluids pre- and post-procedure to flush contrast dye from the renal tubules.

• Hemodialysis Nursing Priorities:

  • Holding Medications: Hold blood pressure medications, cardiac drugs, and water-soluble vitamins prior to dialysis because treatment will filter them out or precipitate post-dialysis hypotension.

  • Pre- & Post-Dialysis Weights: Weighing patients before and after treatment estimates fluid retention and evaluates the volume of fluid removed.

  • Expected Post-Dialysis Findings: Hypotension is the most common post-treatment finding due to rapid fluid removal21. A slight low-grade temperature elevation is expected from warmed blood circuits, but temperatures ≥101°F (38.3°C) indicate an active infection

Serum Creatinine

Best indicator of kidney function:

• Produced from muscle and protein breakdown (constant rate)

• Excreted solely by the kidneys

• Higher in males and those with greater muscle mass

• Doubling of serum creatinine = 50% reduction in GFR

• Any elevation warrants further assessment

Monitoring: Significant increases over hours/days require urgent reporting to provider

---

Blood Urea Nitrogen (BUN)

Measures kidney excretion of urea nitrogen (protein metabolism by-product):

• Elevated BUN suggests kidney dysfunction

• Also affected by non-kidney factors: low cardiac output, RBC destruction, dehydration

BUN/Creatinine Ratio:

• Increased ratio: Dehydration or low cardiac output (BUN rises faster than creatinine)

• Normal ratio with both elevated: Suggests true kidney dysfunction

---

Glomerular Filtration Rate (GFR)

Best overall indicator of kidney function:

• Normal creatinine clearance: 107-139 mL/min (males), 87-107 mL/min (females)

• Values decrease with age (>40 years) due to age-related GFR decline

GFR estimation:

• Calculated from serum creatinine, age, weight, sex, race

• Can use 24-hour urine collection (or 8-12 hour)

• Not accurate during acute/critical illness

Clinical significance:

• Reduced GFR increases vulnerability to acute kidney injury

• Decreased creatinine clearance may require drug dose adjustments

Alternative marker: Cystatin-C

• Protein produced at constant rate by nucleated cells

• Not influenced by factors affecting BUN/creatinine

• When GFR decreases, cystatin-C increases

• May be better GFR indicator

---

Electrolytes

Monitor these values for kidney function changes:

• Serum potassium, sodium, osmolarity

• Urine specific gravity, albumin-to-creatinine ratio, electrolytes

---

Clinical Application

• Know baseline GFR to assess AKI risk

• Monitor lab values when patient receives nephrotoxic drugs (antibiotics, NSAIDs)

• Combining ≥2 nephrotoxic drugs dramatically increases AKI risk

What do you know about IV Urography precautions in regards to renal diagnostics and therapies?

Intravenous (IV) Urography (also known as IV Pyelography) is a diagnostic imaging procedure used to evaluate renal function and identify structural abnormalities within the urinary tract^[1]. Because this procedure relies on IV radiopaque contrast dye, nurses must implement strict pre- and post-procedure precautions to minimize the risk of contrast-induced nephrotoxicity^[1][2].

---

1. Pre-Procedure Nursing Responsibilities

• Assess Baseline Renal Function: Evaluate baseline Serum Creatinine and BUN levels. IV contrast is typically held if the baseline Creatinine is elevated (&gt; 1.2 mg/dL) or if preexisting renal insufficiency is present to prevent precipitating acute kidney injury.

• Screen for Contrast Allergies: Identify known allergies to iodine, shellfish, or radiopaque contrast media.

• Administer IV Fluids: Initiate IV fluid administration pre-procedure to maintain adequate renal perfusion^[1].

• Bowel Preparation: Complete prescribed bowel prep so that stool and bowel gas do not obstruct clear visualization of the kidneys, ureters, and bladder^[1].

• NPO Status: Ensure the patient remains NPO after midnight prior to the procedure^[1].

• Patient Education & Consent: Educate the patient regarding expected sensations during contrast injection and ensure informed consent is obtained^[1].

---

2. Post-Procedure Nursing Responsibilities

• Ensure Vigorous Hydration: Promote adequate fluid intake (oral or IV) to flush the contrast dye out of the renal tubules and mitigate nephrotoxic injury^[1][3].

• Monitor Renal Lab Markers: Re-assess Serum Creatinine and BUN post-procedure to monitor for delayed declines in kidney function^[1].

• Track Urine Output: Closely monitor hourly urine production, ensuring output stays above the standard baseline threshold of 30 mL/hr

Contrast-Induced Kidney Injury Risk

IV urography uses contrast media that are potentially nephrotoxic. Contrast-induced acute kidney injury (previously called contrast-induced nephropathy) refers to postcontrast kidney injury linked to contrast material administration.

---

High-Risk Patients

Greatest risk in patients who are:

• Older adults

• Dehydrated

• Have preexisting chronic kidney disease (CKD)1

• Have comorbidities: diabetes, heart failure, or current hypotension

• Taking nephrotoxic drugs

---

Prevention Strategies

Hydration protocol:

• IV fluids at 1 mL/kg/hr for 6-12 hours before the imaging test

  • OR

• 3 mL/kg/hr for 1 hour just before the procedure

Purpose: Ensure hydration, dilute contrast medium, and speed urinary elimination

Desired outcome: Urine output of 150 mL/hr for the first 6 hours after contrast administration

Coordination with radiologist: Use the lowest dose of contrast agent in high-risk adults

---

Assessment Before Contrast

Screen patients using assessment questions to identify risk factors before undergoing testing with contrast material.

---

Alternative Option

Cystography/cystourethrography:

• Contrast medium is instilled directly into the bladder (not IV)

• Contrast is not absorbed into the bloodstream3

• Reduces the risk for contrast-induced kidney injury

What is Hemodialysis?

Hemodialysis is an invasive renal replacement therapy used when patients with acute kidney injury or chronic/end-stage kidney disease no longer respond to fluid replacement, diuretics, or conservative medical therapy.

The procedure uses a machine equipped with a dialyzer ("artificial kidney") to filter blood, remove metabolic nitrogenous waste (BUN and Creatinine), and pull off excess fluid and sodium. Heparin is infused during treatment to prevent blood from clotting within the circuit, which elevates systemic bleeding and fall risks.

---

1. Vascular Access Types & Nursing Precautions

• Permanent Access (AV Fistula or AV Graft):

  • AV Fistula: Surgical anastomosis connecting an artery directly to a vein5. Requires 3 to 4 months to mature and heal before it can be used for dialysi.

  • Function Assessment: Assess function before every shift and prior to dialysis by palpating for a thrill (a continuous vibration/buzzing) and auscultating for a bruit (a "whooshing" vascular sound) over the site. Also verify distal pulses in the extremity.

  • Strict Arm Precautions: NEVER take blood pressures, draw blood, start IVs, or perform invasive procedures on the arm containing an AV fistula or graft.

  • Vascular Access Complications: Thrombosis or stenosis, infection, aneurysm formation, ischemia, and heart failure.

• Temporary Access: Dual- or triple-lumen subclavian or internal jugular hemodialysis catheter. Nurses must never flush, dress, or manipulate these temporary catheters—only specialized dialysis staff handle them.

---

2. Pre-Dialysis Nursing Care & Medication Rules

• Pre-Procedure Weight: Weigh the patient immediately before dialysis to evaluate fluid retention and help calculate how much fluid needs to be removed during treatmen.

• Holding Medications: Hold blood pressure/cardiac medications (e.g., beta-blockers like atenolol) and water-soluble vitamins prior to treatment. These drugs will either be filtered out by the dialyzer or precipitate severe post-dialysis hypotension as circulating volume is removed.

---

3. Post-Dialysis Assessment & Clinical Findings

• Expected Post-Dialysis Findings:

  • Hypotension: The most common post-dialysis finding resulting from rapid intravascular volume removal.

  • Weight Loss: Patient weight decreases directly reflecting fluid volume removed.

  • Slight Low-Grade Temperature Elevation: A slight temperature rise is expected because blood is warmed as it passes through the machine circuit.

• Abnormal Assessment Findings & Complications:

  • Fever greater than or equal to 101°F (38.3°C): Abnormal; indicates an active infection requiring workup.

  • Dialysis Disequilibrium Syndrome: Occurs when rapid fluid and solute shifts cause cerebral edema and neurological symptoms (headache, nausea/vomiting, restlessness, confusion, or dizziness)1216. Most common in patients new to dialysis; managed by scheduling shorter initial dialysis runs12more_horiz.

  • Invasive Procedure Precaution: Avoid invasive procedures for 4 to 6 hours after dialysis because systemic heparinization elevates bleeding risks1216.

  • Infectious Diseases: Increased risk for bloodborne pathogens such as Hepatitis B, Hepatitis C, and HIV

Definition

Hemodialysis (HD) is the most common kidney replacement therapy (KRT) used in end-stage kidney disease (ESKD) 1. It removes excess fluids and waste products and restores fluid, electrolyte, and acid-base balance.

HD involves passing the patient's blood through an artificial semipermeable membrane to perform the kidney's filtering and excretion functions.

---

How It Works

Mechanism: Diffusion – movement of molecules from higher to lower concentration

The process:

• Blood and dialysate (dialyzing solution) flow in opposite directions across a semipermeable membrane

• Waste products (nitrogen wastes, excess water, excess electrolytes) move from blood into dialysate

• Some water is removed by osmosis

• Electrolytes move in either direction as needed:

  • Potassium and sodium typically move out of plasma into dialysate

  • Bicarbonate and calcium typically move from dialysate into plasma

Additional fluid removal: Water volume removed by applying positive or negative pressure to the system

Large molecules (RBCs, most plasma proteins) cannot pass through the membrane

---

System Components

• Dialyzer (artificial kidney) with 4 parts: blood compartment, dialysate compartment, semipermeable membrane, enclosed support structure

• Dialysate: Made from water and chemicals; free of waste products or drugs; bacteria cannot pass through membrane (not sterile)

• Vascular access routes

• HD machine with built-in safety features (alarms for vital signs, flow rates, pressures, temperature changes)

Dialysate temperature: Warmed to 100°F (37.8°C) to increase diffusion rate and prevent hypothermia

---

Treatment Schedule

Typical regimen: 3-4 hours, 3 days per week

Patients with some ongoing urine production may need only two 5-6 hour treatments per week

---

Safety Considerations

Requires meticulous care by technicians (machines) and nurses (direct care implementation and supervision)

Potential complications from technical/human error: Hemolysis, air embolism, dialysate error, contamination, exsanguination

What is AV Fistula/AV Graft care?

Arteriovenous (AV) Fistula and AV Graft are long-term permanent vascular access sites created for patients undergoing hemodialysis.

• AV Fistula: Formed by surgically connecting an artery directly to a vein. Once created, it requires 3 to 4 months to mature and heal before it can be used for dialysis treatments.

• AV Graft: Formed by placing a synthetic vascular graft material to connect an artery and a vein.

---

1. Assessing Access Patency (The Priority Assessment)

To ensure the vascular access remains functional and open, the nurse must assess the site prior to dialysis and at the beginning of every shift:

• Palpate for a Thrill: Feel over the access site for a thrill, which is a continuous, buzzing vibration caused by high-velocity arterial blood flow.

• Auscultate for a Bruit: Place a stethoscope over the access site to listen for a bruit, which is a characteristic "whooshing" or swishing vascular sound.

• Check Distal Pulses: Routinely check radial/distal pulses and circulation in the extremity containing the shunt to verify adequate peripheral tissue perfusion.

---

2. Strict Limb Precautions

Protecting the arm with an AV fistula or graft is a critical patient safety priority to prevent clotting or rupture:

• NEVER take a blood pressure on the extremity containing the access.

• NEVER perform venipunctures or draw blood from that arm.

• NEVER insert IV lines or run IV fluids in that arm.

• Educate the patient to avoid carrying heavy objects, wearing tight clothing, or sleeping on the side with the access arm.

---

3. Potential Access Complications

Nurses must monitor the site closely for signs of vascular failure or adverse events:

• Thrombosis or Stenosis: Clotting off or narrowing of the vessel, resulting in a loss of the thrill and bruit.

• Infection: Redness, warmth, purulent drainage, or systemic fever at the access insertion site.

• Aneurysm Formation: Bulging or dilation of the vessel wall due to repeated cannulation or weakness.

• Ischemia ("Steal Syndrome"): Reduced blood supply to the hand/fingers distal to the fistula.

• Heart Failure: Elevated cardiac output demands caused by high-volume arterial-to-venous shunting.

• Hemorrhage: Massive, arterial bleeding if the vessel is ruptured or torn

What Are AV Fistulas and AV Grafts?

Internal arteriovenous (AV) fistulas and AV grafts are the two most common long-term vascular access options for hemodialysis.

AV Fistula:

• Surgically created by connecting an artery to a vein (usually radial or brachial artery to cephalic vein in nondominant arm)

• Increases venous blood flow to 250-400 mL/min needed for effective dialysis

Maturation time: Up to 4 months after surgery before usable; temporary access needed during this period

---

Assessment: Check for Adequate Function

Circulation checks:

• Assess distal pulses and capillary refill in the arm with the access

• Check for bruit (auscultation) or thrill (palpation) over the access site

---

Common Complications

Thrombosis (clotting) – Most frequent complication:

• Caused by high-pressure arterial flow → venous wall thickening → reduced/occluded flow

• Treatment: Thrombolytic drugs, balloon angioplasty for strictures

Infection:

• Usually Staphylococcus aureus introduced during cannulation

• Prevention: Prepare skin with antibacterial agent per agency policy

• For dialysis catheters: Use only manufacturer-recommended cleansing agents (some disinfectants damage catheters)

Aneurysms :

• Caused by repeated needle punctures at the same site

• Large aneurysms may require surgical repair

Ischemia (steal syndrome):

• Fistula decreases arterial blood flow below the access site

• Symptoms: Cold/numb fingers to gangrene

• May require surgical revision

Heart failure:

• Rare: Direct arterial-to-venous shunting in patients with limited cardiac function

• May require fistula revision

---

Prevention Strategies

Follow best practices for caring for patients with AV fistula/graft to prevent complications. Strategies include avoiding repeated needle punctures at the same location and maintaining strict infection control during cannulation

Kidney Transplantation

What is postoperative care in regards to kidney transplantation?

Postoperative care for kidney transplantation focuses on evaluating graft function, preventing and managing surgical or immunologic complications, and preparing the patient for lifelong maintenance therapy.

---

1. Urinary Output & Urologic Management

• Hourly Urine Output Tracking (First 48 Hours): Assess and record urine output every hour for the first 48 hours post-surgery.

• Expected Output Surge: Following a successful transplant, urine output typically surges significantly (well above the standard baseline of 30 mL/hr) as the new organ begins filtering.

• Alert Threshold: A sudden drop or inadequate urine output indicates potential graft failure or obstruction and requires immediate reporting.

---

2. Complications to Monitor

• Organ Rejection: Monitor closely for signs and symptoms of acute or chronic graft rejection.

• Acute Tubular Necrosis (ATN) / Delayed Graft Function: Temporary loss of function resulting from donor organ ischemia/hypoxia during transit prior to implantation.

• Vascular Complications: Watch for renal artery or vein thrombosis (clotting) and renal artery stenosis (narrowing of the renal artery).

• Surgical Site Complications: Assess for incisional hemorrhage, hematoma formation, graft rupture, and wound or systemic infections.

---

3. Immunosuppressive Therapy

• Lifelong Medication Adherence: Patients must maintain lifelong immunosuppressive drug therapy (such as corticosteroids and lymphocyte preparations) to prevent host-versus-graft rejection.

• Infection Risk: Because immunosuppressive medications suppress normal immune defenses, maintain strict infection control measures and monitor closely for fever or other signs of infection.

---

4. Laboratory Monitoring & Psychosocial Support

• Renal Function Labs: Frequently evaluate BUN, Serum Creatinine, GFR, and electrolytes to track how effectively the transplanted kidney is functioning.

• Psychosocial Care: Assess coping mechanisms, family support systems, and psychosocial readiness to ensure long-term compliance with complex medication schedules and follow-up care

Overview

Postoperative care after kidney transplantation requires ongoing physical assessment, especially evaluation of kidney function. The two most common complications are rejection and infection.

---

Urologic Management

Urinary catheter placement:

• For accurate urine output measurement and bladder decompression

• Decompression prevents stretch on sutures and ureter attachment sites

Urine output monitoring:

• Assess at least hourly during the first 48 hours

• Abrupt decrease may indicate: rejection, acute kidney injury (AKI), thrombosis, or obstruction

Urine appearance:

• Pink and bloody immediately post-surgery

• Gradually returns to normal over several days to several weeks

Daily urine specimens:

• Urinalysis, glucose, acetone, specific gravity, culture (if needed)

Catheter care:

• Continuous bladder irrigation may be prescribed to decrease blood clot formation (prevents pressure/graft damage)

• Routine catheter care per agency policy to reduce catheter-associated urinary tract infection (CAUTI)

• Remove as soon as possible (usually 3-5 days post-surgery) to avoid infection

---

Fluid Status Monitoring

Two possible patterns:

• Oliguria: May result from ischemia, AKI, rejection, or other complications

• Diuresis: Especially with kidney from living related donor (LRD)

Fluid overload prevention:

• Can cause hypertension, heart failure, pulmonary edema

Monitoring interventions:

• Daily weights

• Blood pressure every 2-4 hours

• Strict intake and output

• Diuretics/osmotic agents may be prescribed to increase urine output

---

Immunosuppression Considerations

Drug therapy to prevent rejection reduces immunity, which:

• Impairs healing

• Increases infection risk

Infection may present atypically: Low-grade fevers, mental status changes, vague discomfort (not typical symptoms)

What is delayed graft function in regards to kidney transplantation?

Delayed Graft Function (DGF) is a postoperative complication of kidney transplantation where the newly transplanted organ fails to function immediately following surgery.

---

1. Cause & Pathophysiology

• Donor Organ Ischemia & Hypoxia: During donor organ procurement and transport from the donor to the recipient, the kidney is temporarily disconnected from systemic blood circulation and oxygen supply.

• Acute Tubular Necrosis (ATN): This transient period of tissue ischemia and hypoxia causes cell damage and Acute Tubular Necrosis (ATN) within the graft's renal tubules, delaying the organ's ability to filter blood and produce urine right after implantation.

---

2. Clinical Presentation & Assessment Findings

• Expected Transplant Output: Following a successful kidney transplant, urine output should surge significantly and measure well above the standard baseline of 30 mL/hr.

• Abnormal Output in DGF: With delayed graft function, the patient exhibits persistent oliguria or a sudden drop in urine production, accompanied by delayed clearance of metabolic waste (elevated BUN and Serum Creatinine).

---

3. Priority Nursing Interventions & Clinical Care

• Hourly Urine Output Tracking: Closely assess and record urine output every hour for the first 48 hours post-operatively. Any inadequate or declining output must be flagged immediately.

• Laboratory & Electrolyte Monitoring: Track daily trends in BUN, Serum Creatinine, GFR, and electrolytes (especially potassium) to evaluate when tubular recovery begins.

• Temporary Dialysis Support: Patients experiencing delayed graft function may require temporary hemodialysis support to manage fluid volume and waste until the ischemic tubular cells heal and graft function resumes.

• Complication Screening: Differentiate ATN/delayed graft function from other acute post-op complications, including acute organ rejection, renal artery or vein thrombosis, and renal artery stenosis

Definition

Delayed graft function occurs when ischemia from delayed transplantation following harvesting can contribute to acute kidney injury (AKI).

---

Clinical Presentation

Oliguria (decreased urine output) is a key sign:

• Can result from ischemia and AKI

• Also potentially caused by rejection or other complications

---

Management

Dialysis support:

• Newly transplanted patients with AKI may need dialysis

• Continues until adequate urine output returns

• Treatment until BUN and creatinine levels normalize

Diuretics/osmotic agents:

• May be prescribed by the nephrology provider to increase urine output

Diagnostic evaluation:

• Biopsy can be used to determine if oliguria is the result of AKI or rejection

• This distinction is critical for appropriate treatment

---

Monitoring During Delayed Graft Function

Continue close fluid status evaluation:

• Daily weights

• Blood pressure every 2-4 hours

• Strict intake and output measurements

Rationale: Fluid overload can cause hypertension, heart failure, and pulmonary edema

---

Differentiation From Other Complications

Delayed graft function must be distinguished from:

• Rejection (diagnosed through symptoms, CT/renal scan, kidney biopsy)

• Thrombosis (sudden decrease in urine output within first 2-3 days; requires emergency surgery)

• Obstruction

What are the signs/symptoms of rejection in regards to kidney transplantation?

What labs to monitor for kidney transplantation?

What is immunosuppressive therapy in regards to kidney transplantation?